Steven H. Lin, M.D., Ph.D.

Peer-Reviewed Articles

1. Wang, K, Ye, R, Bai, S, Xiao, Z, Yang, L, Li, J, Tang, C, Sei, E, Peng, J, Casasent, A, Lin, SH, Nagi, C, Thompson, A, Krishnamurthy, S, Navin, N. Coalescing single-cell genomes and transcriptomes to decode breast cancer progression. Cell 188(22):6355-6369.e16, 2025. e-Pub 2025. PMID: 40912251.
2. Adams, DL, Cristofanilli, M, Lin, SH, Bergan, RC, Ho, TH, Marks, JR, Martin, SS, Edelman, MJ, Chumsri, S, Hager, EJ, Tang, CM, Tsai, S, Alpaugh, RK. Phenotyping and clinical utility of phagocytic polyploid giant cancer macrophages in blood. Cancer Letters 631, 2025. e-Pub 2025. PMID: 40912599.
3. Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, Team D, Lee J, Lee J, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, S Kim BY, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647(8089):488-497, 2025. e-Pub 2025. PMID: 41125896.
4. Lin, SH, Subbiah, V, Cohen, E, Li, Z, Lu, YJ, Son, YL, Lyu, Y, Gao, H, Jayachandran, G, Neri, S, Sharma, A, Fang, PQ, Karp, DD, Hong, DS, Rodon Ahnert, J, Yu, H, Peng, J, Lloyd, GK, Tonra, JR, Reuben, JM, Huang, L, Fu, S. Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers. Med 6(10), 2025. e-Pub 2025. PMID: 40580957.
5. Saad, M, Showkatian, E, Verma, V, Al Tashi, Q, Aminu, M, Xu, X, Mohamed, MQ, Salehjahromi, M, Sujit, S, Kitsel, Y, Lin, SH, Liao, Z, Gandhi, S, Qian, DC, Jaffray, D, Chung, C, Vokes, N, Zhang, J, Jack Lee, J, Heymach, JV, Wu, J, Chang, JY. Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC. Journal for immunotherapy of cancer 13(10), 2025. e-Pub 2025. PMID: 41052882.
6. Ahn M, Lin SH, Yang C, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y. Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study. Lung Cancer 209, 2025. e-Pub 2025. PMID: 41151357.
7. Moding, EJ, Esfahani, MS, Jin, C, Hui, AB, Nabet, BY, Liu, Y, Chabon, JJ, Binkley, MS, Kurtz, DM, Hamilton, EG, Chaudhuri, AA, Liu, CL, Li, Z, Bonilla, RF, Jiang, AL, Lau, B, Lopez, PB, He, J, Qiao, Y, Xu, T, Yao, L, Gandhi, S, Liao, Z, Das, M, Ramchandran, K, Padda, SK, Neal, JW, Wakelee, HA, Gensheimer, MF, Loo, BW, Li, R, Lin, SH, Alizadeh, AA, Diehn, M. Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer. Cancer discovery 15(8):1609-1629, 2025. e-Pub 2025. PMID: 40299851.
8. Populaire, P, Defraene, G, Liu, Y, Titt, U, Yepes, P, Depypere, L, Nafteux, PR, Mohan, R, Lin, SH, Haustermans, K. Dose to the left ventricle is associated to the risk of acute cardiac toxicity in patients with esophageal cancer undergoing trimodality treatment. Radiotherapy and Oncology 209, 2025. e-Pub 2025. PMID: 40550424.
9. Yu, D, Kane, MJ, Chen, Y, Lin, SH, Mohan, R, Hobbs, BP. Bayesian Counterfactual Machine Learning Individualizes Radiation Modality Selection to Mitigate Immunosuppression. JCO Clinical Cancer Informatics 9:e2500058, 2025. e-Pub 2025. PMID: 40920994.
10. Zhang, B, Shah, K, Parma, M, Wang, K, Singhi, EK, Lewis, WE, Rivera, MJ, Altan, M, Pozadzides, JV, Le, X, Vokes, N, Fossella, FV, O'Brien, BJ, Wang, C, Tom, MC, Beckham, TH, Swanson, T, Bronk, JK, Lin, SH, Vega, MF, Jacome, J, Halliday, A, Vailati Negrao, M, Zhang, J, Gibbons, DL, Heymach, JV, Byers, LA, Gay, CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series. Journal of Thoracic Oncology 20(8):1131-1138, 2025. e-Pub 2025. PMID: 40126456.
11. Odwuor, A, Lee, PP, Chang, JY, Gandhi, S, Liao, Z, Lin, SH, Chen, A, Nguyen, Q, O'Reilly, M, Chun, SG, Bronk, JK, Qian, DC, Ning, M. Outcomes and Toxicity following 3 or More Definitive Courses of Thoracic Radiation Therapy for Non-Small Cell Lung Cancer. Clinical Lung Cancer 26(5):384-392, 2025. e-Pub 2025. PMID: 40318943.
12. Lei, G, Sun, M, Cheng, J, Ye, R, Lu, Z, Horbath, A, Huo, D, Wu, S, Alapati, A, Aggarwal, S, Xu, Z, Mao, C, Yan, Y, Yao, J, Li, Q, Chen, X, Lee, H, Zhuang, L, Jiang, D, Pataer, A, Roth, JA, Navin, N, Koong, AC, You, MJ, Lin, SH, Gan, B. Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance. Cancer cell 43(6):1076-1092.e5, 2025. e-Pub 2025. PMID: 40215978.
13. Liu, K, Titt, U, Esplen, NM, Connell, L, Konradsson, E, Yang, M, Wang, X, Takaoka, T, Li, Z, Koong, A, Mitra, D, Mohan, R, Loo, BW, Lin, SH, Schueler, E. Discordance in Acute Gastrointestinal Toxicity between Synchrotron-Based Proton and Linac-based Electron Ultra-High Dose Rate Irradiation. International Journal of Radiation Oncology Biology Physics 122(2):491-501, 2025. e-Pub 2025. PMID: 39862897.
14. Damen, PJ, Peters, M, Hobbs, BP, Chen, Y, Titt, U, Nout, RA, Mohan, R, Lin, SH, van Rossum, P. Defining the Optimal Radiation-induced Lymphopenia Metric to Discern Its Survival Impact in Esophageal Cancer. International Journal of Radiation Oncology Biology Physics 122(1):31-42, 2025. e-Pub 2025. PMID: 39755214.
15. Liu, K, Waldrop, T, Aguilar, E, Mims, N, Neill, D, Delahoussaye, AM, Li, Z, Swanson, DM, Lin, SH, Koong, A, Taniguchi, C, Loo, BW, Mitra, D, Schueler, E. Redefining FLASH Radiation Therapy. International Journal of Radiation Oncology Biology Physics 121(4):1063-1076, 2025. e-Pub 2025. PMID: 39424078.
16. Palmiero, A, Liu, K, Colnot, J, Chopra, N, Neill, D, Connell, L, Velasquez, B, Koong, A, Lin, SH, Balter, PA, Tailor, RC, Robert, C, Germond, JF, Gonçalves Jorge, P, Geyer, R, Beddar, S, Moeckli, R, Schueler, E. On the acceptance, commissioning, and quality assurance of electron FLASH units. Medical physics 52(2):1207-1223, 2025. e-Pub 2025. PMID: 39462477.
17. Abana, CO, Carriere, P, Damen, PJ, van Rossum, P, Yoder, A, Bravo, PL, Wei, X, Pollard-Larkin, JM, Nitsch, PL, Murphy, MB, Hofstetter, WL, Liao, Z, Lin, SH. Comparative Outcomes and Toxicity in Patients With Esophageal Cancer After Trimodality Therapy With Step-and-Shoot Intensity-Modulated Radiation Therapy Versus Volumetric Modulated Arc Therapy. Clinical Oncology 38, 2025. e-Pub 2025. PMID: 39706143.
18. Dudzinski, SO, Cabanillas, ME, Hamidi, S, Marczyk, VR, Busaidy, NL, Dadu, R, Welsh, J, Hu, MI, Gunn, GB, Wang, C, Waguespack, SG, Phan, J, Beckham, TH, Chang, JY, Sherman, SI, Reddy, JP, Ying, AK, O'Reilly, M, Chen, A, Lee, A, Gandhi, S, Liao, Z, Ludmir, EB, Nguyen, Q, Lin, SH, Zafereo, M, Ning, M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2025. e-Pub 2025. PMID: 39662038.
19. Nassar, AH, Jayakrishnan, R, Feng, J, Shepherd, FA, Adib, E, Cheung, JM, Lin, JJ, Liu, Y, Lin, SH, Parikh, K, Sridhar, A, Shakya, P, Dilling, TJ, Kaldas, D, Gray, J, Lobachov, A, Bar, J, Lüders, H, Grohe, C, Gupta, S, Leal, TA, Fitzgerald, BG, Crowley, F, Fujiwara, Y, Marron, TU, Wilgucki, M, Reuss, J, Chen, L, Sankar, K, Aredo, JV, Neal, JW, Wakelee, HA, Thummalapalli, R, Yu, HA, Whitaker, R, Velazquez, AI, Ragavan, M, Cortellini, A, Kwiatkowski, DJ, Naqash, AR, Goldberg, SB, Kim, SY. Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. Journal of Thoracic Oncology 20(1):109-118, 2025. e-Pub 2025. PMID: 39260522.
20. Lin SH, Subbiah V, Cohen EN, Li Z, Lu J, Son YL, Lyu Y, Gao H, Jayachandran G, Neri S, Sharma A, Fang P, Karp D, Hong D, Rodon J, Yu H, Peng J, Lloyd K, Tonra JR, Reuben JM, Huang L, Fu S. Plinabulin Following Radiation Enhances Dendritic Cell Maturation and Checkpoint Inhibitor Retreatment of Relapsed/Refractory Cancers. Med. e-Pub 2025.
21. Ohannesian, N, Mallick, MS, He, J, Qiao, Y, Li, N, Shaitelman, SF, Tang, C, Shinn, EH, Hofstetter, WL, Goltsov, A, Hassan, MM, Hunt, KK, Lin, SH, Shih, WC. Plasmonic nano-aperture label-free imaging of single small extracellular vesicles for cancer detection. Communications Medicine 4(1), 2024. e-Pub 2024. PMID: 38796532.
22. Chu, Y, Zhu, C, Hobbs, BP, Chen, Y, van Rossum, P, Grassberger, C, Zhi, D, Lin, SH, Mohan, R. Personalized Composite Dosimetric Score-Based Machine Learning Model of Severe Radiation-Induced Lymphopenia Among Patients With Esophageal Cancer. International Journal of Radiation Oncology Biology Physics 120(4):1172-1180, 2024. e-Pub 2024. PMID: 38797500.
23. Soto-Lanza, F, Glick, L, Chan, C, Zhong, L, Wilson, NR, Faiz, S, Gandhi, S, Naing, A, Heymach, JV, Shannon, VR, Franco Vega, M, Liao, Z, Lin, SH, Palaskas, NL, Wu, J, Shroff, G, Altan, M, Sheshadri, A. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical Lung Cancer 25(7):624-633.e2, 2024. e-Pub 2024. PMID: 39183094.
24. Ning, M, Odwuor, A, Chang, JY, Gandhi, S, Liao, Z, Lin, SH, Chen, A, Welsh, J, Nguyen, Q, O'Reilly, M, Chun, SG, Bronk, JK, Qian, DC, Lee, PP. Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. Cancers 16(21), 2024. e-Pub 2024. PMID: 39518028.
25. Nead, KT, Kim, T, Joo, L, McDowell, TL, Wong, J, Chan, IC, Brock, E, Zhao, J, Xu, T, Tang, C, Lee, CL, Abe, J, Bolton, KL, Liao, Z, Scheet, PA, Lin, SH. Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes. Blood Advances 8(19):5215-5224, 2024. e-Pub 2024. PMID: 38830141.
26. Chen, Y, Chu, Y, van Rossum, P, Grassberger, C, Lin, SH, Mohan, R, Hobbs, BP. Radiation-Induced Lymphopenia is a Causal Mediator of Survival After Chemoradiation Therapy for Esophagus Cancer. Advances in Radiation Oncology 9(10), 2024. e-Pub 2024. PMID: 39258141.
27. Hu, Z, Mohan, R, Chu, Y, Wang, X, van Rossum, P, Chen, Y, Grayson, ME, Gearhardt, AG, Grassberger, C, Zhi, D, Hobbs, BP, Lin, SH, Cao, W. Clinical Translation of a Deep Learning Model of Radiation-Induced Lymphopenia for Esophageal Cancer. International Journal of Particle Therapy 13, 2024. e-Pub 2024. PMID: 39228692.
28. Lyu, Y, Lin, SH, Wu, H, Li, Z. SCIntRuler. Bioinformatics 40(9), 2024. e-Pub 2024. PMID: 39226185.
29. van der Zijden, CJ, Lagarde, S, Mostert, B, Nuyttens, JJ, Spaander, MC, Wijnhoven, BP, Van Sandick, JW, van Dieren, JM, Voncken, FE, Pierie, JP, Fiets, WE, Rosman, C, Siersema, PD, Rütten, H, Nieuwenhuijzen, GA, Creemers, GJ, Schoon, EJ, van der Sangen, MJ, Verschoor, AJ, Quispel, R, Sosef, MN, Buijsen, J, Hartgrink, HH, Slingerland, M, Heisterkamp, J, Beerepoot, LV, Hazen, WL, Rozema, T, Muller, K, Kouwenhoven, EA, Law, SK, Chan, WW, Wong, I, Li, Z, Chao, YK, Wu, IC, Wu, CE, Yap, WK, Park, SY, Takeuchi, H, Booka, E, Kato, K, Yoshinori, I, Lin, SH, Piessen, G, Turpin, A, Taillez, A, Castoro, C, Bastoni, A, Maselli, R. International Expert Consensus on Semantics of Multimodal Esophageal Cancer Treatment. Annals of surgical oncology 31(8):5075-5082, 2024. e-Pub 2024. PMID: 38717548.
30. Adams, DL, Lin, SH, Pass, HI, Edelman, MJ, Iwase, T, Ueno, NT, Bergan, RC, Tsai, S, Aldakkak, M, Aft, R, Watson, M, Kim, A, Chikamatsu, K, Hayashi, M, Loeb, DM, Pinto, N, Ho, TH, Gaston, SM, Punnen, S, Marks, JR. Polyploid circulating stromal cells in blood to identify invasive solid tumors and to prognosticate for highly aggressive cancer subtypes. Journal of Clinical Oncology 42(16):3053, 2024. e-Pub 2024.
31. Nassar, AH, Kim, SY, Aredo, JV, Feng, J, Shepherd, F, Xu, C, Kaldas, D, Gray, J, Dilling, TJ, Neal, JW, Wakelee, HA, Liu, Y, Lin, SH, Abuali, T, Amini, A, Nie, Y, Patil, T, Lobachov, A, Bar, J, Fitzgerald, BG, Fujiwara, Y, Marron, TU, Thummalapalli, R, Yu, HA, Owen, D, Sharp, J, Farid, S, Rocha, P, Arriola, E, D'Aiello, A, Cheng, H, Whitaker, R, Parikh, K, Ashara, Y, Chen, L, Sankar, K, Harris, JP, Nagasaka, M, Ayanambakkam, A, Velazquez, AI, Ragavan, M, Lin, JJ, Piotrowska, Z, Wilgucki, M, Reuss, J, Lüders, H, Grohé, C, Baena Espinar, J, Feiner, E, Punekar, S, Gupta, S, Leal, TA, Kwiatkowski, DJ, Mak, RH, Adib, E, Naqash, AR, Goldberg, SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC. Journal of Thoracic Oncology 19(6):928-940, 2024. e-Pub 2024. PMID: 38278303.
32. Yan Chu, Cong Zhu, Brian P. Hobbs, Yiqing Chen, Peter S.N. van Rossum, Clemens Grassberger, Degui Zhi, Lin SH, Radhe Mohan. Personalized Composite Dosimetric Score−Based Machine Learning Model of Severe Radiation-Induced Lymphopenia Among Patients With Esophageal Cancer. Red Journal. e-Pub 2024.
33. Corrigan, KL, Xu, T, Sasaki, Y, Lin, R, Chen, AB, Welsh, JW, Lin, SH, Chang, JY, Ning, MS, Gandhi, S, O'Reilly, MS, Gay, CM, Altan, M, Lu, C, Cascone, T, Koutroumpakis, E, Sheshadri, A, Zhang, X, Liao, L, Zhu, XR, Heymach, JV, Nguyen, Q, Liao, Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiotherapy and Oncology 193, 2024. e-Pub 2024. PMID: 38311031.
34. Kim, YS, Lee, SH, Park, AH, Wu, C, Hong, BK, Jung, H, Lin, SH, Yoo, S. BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1. Journal for immunotherapy of cancer 12(3), 2024. e-Pub 2024. PMID: 38485289.
35. Damen, PJ, van Rossum, P, Chen, Y, Abana, CO, Liao, Z, Hobbs, BP, Mohan, R, Blum Murphy, M, Hofstetter, WL, Lin, SH. Comparing 90-Day Postoperative Mortality After Neoadjuvant Proton-Based Versus Photon-Based Chemoradiotherapy for Esophageal Cancer. International Journal of Particle Therapy 11, 2024. e-Pub 2024. PMID: 38757082.
36. Abana, CO, Damen, PJ, van Rossum, P, Bravo, PL, Wei, X, Pollard-Larkin, JM, Nitsch, PL, Murphy, MB, Hofstetter, WL, Liao, Z, Lin, SH. Esophageal Cancer Outcomes After Definitive Chemotherapy With Intensity Modulated Proton Therapy. International Journal of Particle Therapy 11, 2024. e-Pub 2024. PMID: 38757075.
37. Wang, X, van Rossum, P, Chu, Y, Hobbs, BP, Grassberger, C, Hong, TS, Liao, Z, Yang, J, Zhang, X, Netherton, T, Mohan, R, Lin, SH. Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Comprehensive Analysis of Randomized Phase 2B Trial of Proton Beam Therapy Versus Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics 118(2):368-377, 2024. e-Pub 2024. PMID: 37652304.
38. Tate, MK, Hernandez, M, Chang, JY, Lin, SH, Liao, Z, Koshy, SM, Skinner, H, Chun, SG. Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer. Anticancer research 44(1):133-137, 2024. e-Pub 2024. PMID: 38159979.
39. Eads, JR, Graham, NT, Gibson, MK, Rajdev, L, Bapsi Chakravarthy, A, Khullar, OV, Lin, SH, Wistuba, II, Agarwal, R, Blazar, M, Mehta, DR, Baghdadi, TA, Jin, N, Massa, RC, Hamilton, SR, Staley, CA, Wong, TZ, O'Dwyer, PJ. A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
40. Ellsworth, SG, van Rossum, P, Mohan, R, Lin, SH, Grassberger, C, Hobbs, BP. Declarations of Independence. International Journal of Radiation Oncology Biology Physics 117(5):1054-1062, 2023. e-Pub 2023. PMID: 37406827.
41. Altan, M, Soto, F, Xu, T, Wilson, NR, Franco Vega, M, Simbaqueba Clavijo, CA, Shannon, VR, Faiz, S, Gandhi, S, Lin, SH, Lopez, PB, Zhong, L, Akhmedzhanov, FO, Godoy, M, Shroff, G, Wu, J, Khawaja, F, Kim, ST, Naing, A, Heymach, JV, Daniel-MacDougall, CR, Liao, Z, Sheshadri, A. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clinical Oncology 35(10):630-639, 2023. e-Pub 2023. PMID: 37507279.
42. Lin SH. Statin Use and Chemoradiation in Esophageal Squamous Cell Carcinomas: Ready for Prime Time?. J Thorac Oncol 18(8):970-971, 2023. e-Pub 2023. PMID: 37479326.
43. Saad, MB, Hong, L, Aminu, M, Vokes, N, Chen, P, Salehjahromi, M, Qin, K, Sujit, S, Lu, X, Young, E, Al-Tashi, Q, Qureshi, R, Wu, CC, Carter, B, Lin, SH, Lee, PP, Gandhi, S, Chang, JY, Li, R, Gensheimer, MF, Wakelee, HA, Neal, JW, Lee, HS, Cheng, C, Velcheti, V, Lou, Y, Petranovic, M, Rinsurongkawong, W, Le, X, Rinsurongkawong, V, Spelman, AR, Elamin, YY, Vailati Negrao, M, Skoulidis, F, Gay, CM, Cascone, T, Antonoff, MB, Sepesi, B, Lewis, J, Wistuba, II, Hazle, JD, Chung, C, Jaffray, D, Gibbons, DL, Vaporciyan, AA, Lee, JJ, Heymach, JV, Zhang, J, Wu, J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning. The Lancet Digital Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
44. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
45. Abe, J, Imanishi, M, Li, S, Zhang, A, Ko, KA, Samanthapudi, VS, Lee, LL, Bojorges, AP, Gi, YJ, Hobbs, BP, Deswal, A, Herrmann, J, Lin, SH, Chini, EN, Shen, YH, Schadler, KL, Nguyen, TM, Gupte, AA, Reyes-Gibby, CC, Yeung, SJ, Abe, RJ, Olmsted-Davis, EA, Krishnan, S, Dantzer, R, Palaskas, NL, Cooke, J, Pownall, HJ, Yoshimoto, M, Fujiwara, K, Hamilton, DJ, Burks, JK, Wang, G, Le, NT, Kotla, S. An ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis. Circulation research 133(1):25-44, 2023. e-Pub 2023. PMID: 37264926.
46. Kim Y, Chamseddine I, Cho Y, Kim JS, Mohan R, Shusharina N, Paganetti H, Lin S, Yoon HI, Cho S, Grassberger C. Neural network based ensemble model to predict radiation induced lymphopenia after concurrent chemo-radiotherapy for non-small cell lung cancer from two institutions. Neoplasia 39:100889, 2023. e-Pub 2023. PMID: 36931040.
47. Valdés Zayas A, Kumari N, Liu K, Neill D, Delahoussaye A, Gonçalves Jorge P, Geyer R, Lin SH, Bailat C, Bochud F, Moeckli R, Koong AC, Bourhis J, Taniguchi CM, Herrera FG, Schüler E. Independent Reproduction of the FLASH Effect on the Gastrointestinal Tract: A Multi-Institutional Comparative Study. Cancers (Basel) 15(7), 2023. e-Pub 2023. PMID: 37046782.
48. Ellsworth SG, Mohan R, Lin SH. RE: Venkatesulu et al. (Letter to the Editor). Radiother Oncol 181:109490, 2023. e-Pub 2023. PMID: 36736591.
49. Kowalchuk RO, Spears GM, Morris LK, Owen D, Yoon HH, Jethwa K, Chuong MD, Ferris MJ, Haddock MG, Hallemeier CL, Wigle D, Lin SH, Merrell KW. Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer. Front Oncol 13:1081024, 2023. e-Pub 2023. PMID: 36845682.
50. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
51. McCullum L, Shin J, Xing S, Beekman C, Schuemann J, Hong T, Duda D, Mohan R, Lin S, Correa-Alfonso CM, Domal S, Withrow J, Bolch W, Paganetti H, Grassberger C. Predicting Severity of Radiation Induced Lymphopenia in Individual Proton Therapy Patients for Varying Dose Rate and Fractionation Using Dynamic 4-Dimensional Blood Flow Simulations. Int J Radiat Oncol Biol Phys 116(5):1226-1233, 2023. e-Pub 2023. PMID: 36739919.
52. Cohen EN, Jayachandran G, Gao H, Peabody P, McBride HB, Alvarez FD, Bravo PL, Qiao W, Liu S, Yao L, Lin SH, Reuben JM. Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally advanced non-small cell lung cancer. Transl Lung Cancer Res 12(1):109-126, 2023. e-Pub 2023. PMID: 36762061.
53. Nguyen, MT, Imanishi, M, Li, S, Chau, KM, Banerjee, P, Velatooru, LR, Ko, KA, Samanthapudi, VS, Gi, YJ, Lee, LL, Abe, RJ, Fujiwara, E, Deswal, A, Lin, SH, Palaskas, NL, Dantzer, R, Fujiwara, K, Borchrdt, MK, Turcios, EB, Olmsted-Davis, EA, Kotla, S, Cooke, J, Wang, G, Abe, J, Le, NT. Endothelial activation and fibrotic changes are impeded by laminar flow-induced CHK1-SENP2 activity through mechanisms distinct from endothelial-to-mesenchymal cell transition. Frontiers in Cardiovascular Medicine 10, 2023. e-Pub 2023. PMID: 37711550.
54. van Rossum, P, Juan-Cruz, C, Stam, B, Rossi, MM, Lin, SH, Abravan, A, Belderbos, JS, Sonke, JJ. Severe radiation-induced lymphopenia during concurrent chemoradiotherapy for stage III non-small cell lung cancer. Frontiers in Oncology 13, 2023. e-Pub 2023. PMID: 38023221.
55. De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol 7:e2200540, 2023. e-Pub 2023. PMID: 36716413.
56. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
57. Zhou N, Hofstetter WL, Working Group ESCC, Mitchell KG, Bayley EM, Ajani JA, Antonoff MB, Betancourt SL, Blum-Murphy M, Feldman HA, Lin SH, Maru DM, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Weston BR. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg 114(6):2032-2040, 2022. e-Pub 2022. PMID: 34883083.
58. Kim, HH, Venkatesulu, BP, McMillan, MT, Verma, V, Lin, SH, Chang, JY, Welsh, J. Local Therapy for Oligoprogressive Disease. International Journal of Radiation Oncology Biology Physics 114(4):676-683, 2022. e-Pub 2022. PMID: 35973624.
59. Xu, T, Wu, Lr, Gandhi, S, Jing, W, Nguyen, Q, Chen, A, Chang, JY, Nurieva, R, Sheshadri, A, Altan, M, Lee, PP, Lin, SH, Liao, Z. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiotherapy and Oncology 176:149-156, 2022. e-Pub 2022. PMID: 36209942.
60. Ellsworth, SG, Yalamanchali, A, Lautenschlaeger, T, Grossman, SA, Grassberger, C, Lin, SH, Mohan, R. Lymphocyte Depletion Rate as a Biomarker of Radiation Dose to Circulating Lymphocytes During Fractionated Partial-Body Radiation Therapy. Advances in Radiation Oncology 7(5), 2022. e-Pub 2022. PMID: 35928987.
61. Wang, J, Xu, T, Wu, Lr, Lopez, PB, Grassberger, C, Ellsworth, SG, Mohan, R, Hobbs, BP, Blumenschein, GR, Tu, J, Altan, M, Lee, PP, Liao, Z, Lin, SH. Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clinical and Research Reports 3(9), 2022. e-Pub 2022. PMID: 36089921.
62. Wang J, Xu T, Wu L, Lopez P, Grassberger C, Ellsworth SG, Mohan R, Hobbs BP, Blumenschein GR, Tu J, Altan M, Lee P, Liao Z, Lin SH. Severe Radiation-induced Lymphopenia Attenuates the Benefit of Durvalumab after Concurrent Chemoradiotherapy for Non-Small Cell Lung Cancer. JTO Clin Res Rep, 2022. e-Pub 2022.
63. Yang, M, Wang, X, Guan, F, Titt, U, Iga, K, Jiang, D, Takaoka, T, Tootake, S, Katayose, T, Umezawa, M, Schueler, E, Frank, SJ, Lin, SH, Sahoo, N, Koong, A, Mohan, R, Zhu, XR. Adaptation and dosimetric commissioning of a synchrotron-based proton beamline for FLASH experiments. Physics in medicine and biology 67(16), 2022. e-Pub 2022. PMID: 35853442.
64. Duan, J, Tan, F, Bi, N, Chen, C, Chen, K, Cheng, Y, Chu, Q, Ge, D, Hu, J, Huang, Y, Jiang, T, Long, H, Lu, Y, Shi, MQ, Wang, JL, Wang, Q, Yang, F, Yang, N, Yao, Y, Ying, J, Zhou, CC, Zhou, Q, Zhou, Q, Bongiolatti, S, Brunelli, A, Fiorelli, A, Gobbini, E, Gridelli, C, John, T, Kim, JJ, Lin, SH, Metro, G, Minervini, F, Novoa, N, Owen, D, Rodríguez, MC, Sakanoue, I, Scarci, M, Suda, K, Tabbò, F, Chun Tam, TC, Tsuchida, M, Uchino, J, Voltolini, L, Wang, J, Gao, S. Expert consensus on perioperative treatment for non-small cell lung cancer. Translational Lung Cancer Research 11(7):1247-1267, 2022. e-Pub 2022. PMID: 35958323.
65. Duan J, Tan F, Bi N, Chen C, Chen KN, Cheng Y, Chu Q, Ge D, Hu J, Huang Y, Jiang T, Long H, Lu Y, Shi M, Wang J, Wang Q, Yang F, Yang N, Yao Y, Ying J, Zhou C, Zhou Q, Zhou Q, Bongiolatti S, Brunelli A, Fiorelli A, Gobbini E, Gridelli C, John T, Kim JJ, Lin SH, Metro G, Minervini F, Novoa NM, Owen DH, Rodriguez M, Sakanoue I, Scarci M, Suda K, Tabbò F, Chun Tam TC, Tsuchida M, Uchino J, Voltolini L, Wang J, Gao S. Expert consensus on perioperative treatment for non-small cell lung cancer. Translational Lung Cancer Research 11(7):1247-1267, 2022. e-Pub 2022.
66. Yang M, Wang X, Guan F, Titt U, Iga K, Jiang D, Takaoka T, Totake S, Katayose T, Umezawa M, Schüler E, Frank SJ, Lin SH, Sahoo N, Koong AC, Mohan R, Zhu XR. Adaptation and dosimetric commissioning of a synchrotron-based proton beamline for FLASH experiments. Phys Med Biol, 2022. e-Pub 2022.
67. Lin, SH, Liao, K, Lei, X, Verma, V, Shaaban, SG, Lee, PP, Chen, A, Koong, A, Hoftstetter, WL, Frank, SJ, Liao, Z, Shih, YT, Giordano, SH, Smith, GL. Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. International Journal of Particle Therapy 9(1):18-27, 2022. e-Pub 2022. PMID: 35774487.
68. Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, Chang JY, Lin SH. A Systematic Review of Cost-Effectiveness Studies of Stereotactic Radiotherapy for Cancer Oligometastases. Int J Radiat Oncol Biol Phys, 2022. e-Pub 2022.
69. Lin SH, Liao K, Lei X, Verma V, Shaaban S, Lee P, Chen AB, Koong AC, Hoftstetter WL, Frank SJ, Liao Z, Shih YT, Giordano SH, Smith GL. Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. Int J Part Ther 9(1):18-27, 2022. e-Pub 2022.
70. Hsieh RC, Krishnan S, Wu RC, Boda AR, Liu A, Winkler M, Hsu WH, Lin SH, Hung MC, Chan LC, Bhanu KR, Srinivasamani A, De Azevedo RA, Chou YC, DePinho RA, Gubin M, Vilar E, Chen CH, Slay R, Jayaprakash P, Hegde SM, Hartley G, Lea ST, Prasad R, Morrow B, Couillault CA, Steiner M, Wang CC, Venkatesulu BP, Taniguchi C, Kim YSB, Chen J, Rudqvist NP, Curran MA. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Sci Immunol 7(72), 2022. e-Pub 2022.
71. Hsieh, RE, Krishnan, S, Wu, RC, Boda, A, Liu, A, Winkler, M, Hsu, WH, Lin, SH, Hung, MC, Chan, LC, Bhanu, KR, Srinivasamani, A, de Azevedo, RA, Chou, YC, DePinho, RA, Gubin, M, Vilar Sanchez, E, Chen, CH, Slay, RB, Jayaprakash, P, Hegde, SM, Hartley, G, Lea, ST, Prasad, R, Morrow, B, Couillault, CA, Steiner, M, Wang, CC, Venkatesulu, BP, Taniguchi, C, Betty Kim, YS, Chen, J, Rudqvist, N, Curran, M. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. Science Immunology 7(72), 2022. e-Pub 2022. PMID: 35687697.
72. Ebrahimi, S, Lim, G, Hobbs, BP, Lin, SH, Mohan, R, Cao, W. A hybrid deep learning model for forecasting lymphocyte depletion during radiation therapy. Medical physics 49(5):3507-3522, 2022. e-Pub 2022. PMID: 35229311.
73. Payne RG, Anker CJ, Sprague BL, No HJ, Lin SH, Lester-Coll NH. Active Surveillance for Early Stage Lung Cancer. Clin Lung Cancer 23(3):226-235, 2022. e-Pub 2022.
74. Damen PJJ, Kroese TE, Peters M, Lin SH, Verhoeff JJC, van Rossum PSN. In Reply to Chow and Simone. Int J Radiat Oncol Biol Phys 113(1):236-237, 2022. e-Pub 2022. PMID: 35427556.
75. Bostock, I, Zhou, N, Antonoff, MB, Blum Murphy, M, Lin, SH, Maru, DM, Mehran, RJ, Rajaram, R, Rice, DC, Sepesi, B, Swisher, SG, Vaporciyan, AA, Walsh, GL, Hofstetter, WL. Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Diseases of the Esophagus 35(4), 2022. e-Pub 2022. PMID: 34897440.
76. Nowakowska, M, Kim, T, Thompson, MR, Bolton, KL, Deswal, A, Lin, SH, Scheet, PA, Wehner, M, Nead, KT. Association of clonal hematopoiesis mutations with clinical outcomes. American journal of hematology 97(4):411-420, 2022. e-Pub 2022. PMID: 35015316.
77. Bostock IC, Zhou N, Antonoff MB, Murphy MB, Lin SH, Maru D, Mehran R, Rajaram R, Rice D, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Hofstetter W. Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Diseases of the Esophagus 35(4), 2022. e-Pub 2022.
78. Banerjee P, Olmsted-Davis EA, Deswal A, Nguyen MT, Koutroumpakis E, Palaskas NL, Lin SH, Kotla S, Reyes-Gibby C, Yeung SJ, Yusuf SW, Yoshimoto M, Kobayashi M, Yu B, Schadler K, Herrmann J, Cooke JP, Jain A, Chini E, Le NT, Abe JI. Cancer treatment-induced NAD+ depletion in premature senescence and late cardiovascular complications. J Cardiovasc Aging, 2022. e-Pub 2022.
79. Haque W, Singh A, Park HS, Teh BS, Butler EB, Zeng M, Lin SH, Welsh JW, Chang JY, Verma V. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta Oncol 61(4):403-408, 2022. e-Pub 2022.
80. Gjyshi O, Lin SH, Pezzi TA, Ning MS, Ma J, Liu S, Rusthoven CG. Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases. Clin Lung Cancer 23(2):185-190, 2022. e-Pub 2022.
81. Wang X, Palaskas NL, Hobbs BP, Abe JI, Nead KT, Yusuf SW, Hermann J, Deswal A, SH||B |. The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. Cancers (Basel) 33(5):145-152, 2022. e-Pub 2022. PMID: 35267613.
82. Ebrahimi, S, Lim, G, Hobbs, BP, Lin, SH, Mohan, R, Cao, W. A hybrid deep learning model for forecasting lymphocyte depletion during radiation therapy. Medical Physics:1-16, 2022. e-Pub 2022.
83. Ye, Y, Zhang, Y, Yang, N, Gao, Q, Ding, X, Kuang, X, Bao, R, Zhang, Z, Sun, C, Zhou, B, Wang, L, Hu, Q, Lin, C, Gao, J, Lou, Y, Lin, SH, Diao, L, Liu, H, Chen, X, Mills, GB, Han, L. Profiling of immune features to predict immunotherapy efficacy. Innovation 3(1), 2022. e-Pub 2022. PMID: 34977836.
84. Jing, Y, Chen, X, Li, K, Liu, Y, Zhang, Z, Chen, Y, Liu, Y, Wang, Y, Lin, SH, Diao, L, Wang, J, Lou, Y, Johnson, DB, Chen, X, Liu, H, Han, L. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. Journal for immunotherapy of cancer 10(1), 2022. e-Pub 2022. PMID: 35058327.
85. Haque, W, Singh, A, Park, HS, Teh, BS, Butler, EB, Zeng, M, Lin, SH, Welsh, J, Chang, JY, Verma, V. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta Oncologica 61(4):403-408, 2022. e-Pub 2022. PMID: 34913815.
86. Titt, U, Yang, M, Wang, X, Iga, K, Fredette, N, Schueler, E, Lin, SH, Zhu, XR, Sahoo, N, Koong, A, Zhang, X, Mohan, R. Design and validation of a synchrotron proton beam line for FLASH radiotherapy preclinical research experiments. Medical physics 49(1):497-509, 2022. e-Pub 2022. PMID: 34800037.
87. Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y, Liu Y, Wang Y, Lin SH, Diao L, Wang J, Lou Y, Johnson DB, Chen X, Liu H, Han L. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J Immunother Cancer 10(1):003779, 2022. e-Pub 2022.
88. Nowakowska MK, Kim T, Thompson MT, Bolton KL, Deswal A, Lin SH, Scheet P, Wehner MR, Nead KT. Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis. Am J Hematol, 2022. e-Pub 2022.
89. Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 30:100514, 2022. e-Pub 2022. PMID: 35051703.
90. Titt U, Yang M, Wang X, Iga K, Fredette N, Schueler E, Lin SH, Zhu XR, Sahoo N, Koong AC, Zhang X, Mohan R. Design and validation of a synchrotron proton beam line for FLASH radiotherapy preclinical research experiments. Med Phys 49(1):497-509, 2022. e-Pub 2022.
91. Haque W, Singh A, Park HS, Teh BS, Butler EB, Zeng M, Lin SH, Welsh JW, Chang JY, Verma V. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Clinical Oncology:403-408, 2022. e-Pub 2022.
92. Imanishi M, Cheng H, Kotla S, Deswal A, Le NT, Chini E, Ko KA, Samanthapudi VSK, Lee LL, Herrmann J, Xu X, Reyes-Gibby C, Yeung SJ, Schadler KL, Yusuf SW, Liao Z, Nurieva R, Amir ED, Burks JK, Palaskas NL, Cooke JP, Lin SH, Kobayashi M, Yoshimoto M, Abe JI. Radiation therapy induces immunosenescence mediated by p90RSK. Front Cardiovasc Med 9:988713, 2022. e-Pub 2022. PMID: 36426217.
93. Tomassen ML, Pomp J, van der Stap J, SR van Lindert A, Peters M, Belderbos J, De Ruysscher D, Lin SH, Verhoeff J, van Rossum P. The overall survival impact of prophylactic cranial irradiation in limited-stage small-cell lung cancer: A systematic review and meta-analysis. Clinical and Translational Radiation Oncology 33, 2022. e-Pub 2022.
94. Haque W, Singh A, Park HS, Teh BS, Butler EB, Zeng M, Lin SH, Welsh JW, Chang JY, Verma V. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta Oncol 16:1-6, 2021. e-Pub 2021.
95. Ye Y, Zhang Y, Yang N, Gao Q, Ding X, Kuang X, Bao R, Zhang Z, Sun C, Zhou B, Wang L, Hu Q, Lin C, Gao J, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Profiling of immune features to predict immunotherapy efficacy. Innovation (Camb) 3(1):100194, 2021. e-Pub 2021.
96. Ye Y, Zhang Y, Yang N, Gao Q, Ding X, Kuang X, Bao R, Zhang Z, Sun C, Zhou B, Wang L, Hu Q, Lin C, Gao J, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Profiling of immune features to predict immunotherapy efficacy. Innovation (N.Y) 3(1):100194, 2021. e-Pub 2021.
97. Kotla S, Zhang A, Imanishi M, Ko KA, Lin SH, Gi YJ, Moczygemba M, Isgandarova S, Schadler KL, Chung C, Milgrom SA, Banchs J, Yusuf SW, Amaya DN, Guo H, Thomas TN, Shen YH, Deswal A, Herrmann J, Kleinerman ES, Entman ML, Cooke JP, Schifitto G, Maggirwar SB, McBeath E, Gupte AA, Krishnan S, Patel ZS, Yoon Y, Burks JK, Fujiwara K, Brookes PS, Le NT, Hamilton DJ, Abe JI. Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation. Redox Biol 47:102132, 2021. e-Pub 2021.
98. Wang X, Hobbs B, Gandhi SJ, Muijs CT, Langendijk JA, Lin SH. Current status and application of proton therapy for esophageal cancer. Radiother Oncol 164:27-36, 2021. e-Pub 2021.
99. Wang K, Xiao Z, Yan Y, Ye R, Hu M, Bai S, Sei E, Qiao Y, Chen H, Lim B, Lin SH, Navin NE. Simple oligonucleotide-based multiplexing of single-cell chromatin accessibility. Mol Cell 81(20):4319-4332, 2021. e-Pub 2021.
100. Chuong MD, Hallemeier CL, Li H, Zhu XR, Zhang X, Tryggestad EJ, Yu J, Yang M, Choi JI, Kang M, Liu W, Knopf A, Meijers A, Molitoris JK, Apisarnthanarax S, Giap H, Hoppe BS, Lee P, Chang JY, 2nd SC, Lin SH. Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. Front Oncol 11:748331, 2021. e-Pub 2021.
101. Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB Lin SH, Chang JY Tsao A, Gay CM, Zhu XR, Chang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao Z. Toxicity and survival after intensity-modulated proton therapy versus passive scattering proton therapy for NSCLC. J Thorac Oncol 16(2):269-277, 2021. e-Pub 2021. PMID: 33198942.
102. Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 22(10):1448-1457, 2021. e-Pub 2021.
103. Spiotto MT, Taniguchi CM, Klopp AH, Colbert LE, Lin SH, Wang L, Frederick MJ, Osman AA, Pickering CR, Frank SJ. Biology of the Radio- and Chemo-Responsiveness in HPV Malignancies. Seminars in radiation oncology 31(4):274-285, 2021. e-Pub 2021. PMID: 34455983.
104. Banerjee P, Kotla S, Reddy Velatooru L, Abe RJ, Davis EA, Cooke JP, Schadler K, Deswal A, Herrmann J, Lin SH, Abe JI, Le NT. Senescence-Associated Secretory Phenotype as a Hinge Between Cardiovascular Diseases and Cancer. Front Cardiovasc Med 8:763930, 2021. e-Pub 2021.
105. Zhu C, Mohan R, Lin SH, Jun G, Yaseen A, Jiang X, Wang Q, Cao W, Hobbs BP. Identifying Individualized Risk Profiles for Radiotherapy-Induced Lymphopenia Among Patients With Esophageal Cancer Using Machine Learning. JCO Clin Cancer Inform 5:1044-1053, 2021. e-Pub 2021.
106. Misbah I, Ohannesian N, Qiao Y, Lin SH, Shih WC. Exploring the synergy of radiative coupling and substrate undercut in arrayed gold nanodisks for economical, ultra-sensitive label-free biosensing. IEEE Sens J 21(21):23971-23978, 2021. e-Pub 2021.
107. Lin SH, Willers H, Krishnan S, Sarkaria JN, Baumann M, Lawrence TS. Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. Int J Radiat Oncol Biol Phys, 2021. e-Pub 2021. PMID: 34454045.
108. Kroese TE, Jairam J, Ruurda JP, Lin SH, Mohan R, Mook S, Haitjema S, Hoefer I, Mohammad NH, Peters M, van Hillegersberg R, van Rossum PSN. Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: incidence and external validation of a prediction model. Radiother Oncol, 2021. e-Pub 2021. PMID: 34453954.
109. Willers H, Pan X, Borgeaud N, Korovina I, Koi L, Egan R, Greninger P, Rosenkranz A, Kung J, Liss AS, Parsels LA, Morgan MA, Lawrence TS, Lin SH, Hong TS, Yeap BY, Wirth L, Hata AN, Ott CJ, Benes CH, Baumann M, Krause M. Screening and Validation of Molecular Targeted Radiosensitizers. Int J Radiat Oncol Biol Phys, 2021. e-Pub 2021. PMID: 34343607.
110. Xu T, Meng QH, Gilchrist SC, Lin SH, Lin R, Xu T, Milgrom SA, Gandhi SJ, Wu H, Zhao Y, Lopez-Mattei JC, Mohan R, Liao Z. Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial. Int J Radiat Oncol Biol Phys , 2021. e-Pub 2021. PMID: 34302893.
111. Gjyshi O, Lin SH, Pezzi TA, Ning MS, Ma J, Liu S, Rusthoven CG. Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases. Clin Lung Cancer 23(2):185-190, 2021. e-Pub 2021. PMID: 34419375.
112. Ye R, Qiao Y, Singh PK, Wang Y, He J, Li N, Krishnan S, Lin SH. High-Content Clonogenic Survival Screen to Identify Chemoradiation Sensitizers. Int J Radiat Oncol Biol Phys, 2021. e-Pub 2021. PMID: 34343607.
113. Grant SR, Smith BD, Colbert LE, Nguyen QN, Yu JB, Lin SH, Chen AB. National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer. J Natl Compr Canc Netw:1-6, 2021. e-Pub 2021. PMID: 34044365.
114. Augustyn A, Adams DL, He J, Qiao Y, Verma V, Liao Z, Tang CM, Heymach JV, Tsao AS, Lin SH. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer 22(3):451-465, 2021. e-Pub 2021. PMID: 32798130.
115. Chapman BV, Ning MS, Farnia B, Mesko S, Lin SH, Tang C, Allen PK, Liao Z, Chang JY, Komaki R, Mehran RJ, Gandhi SJ, Gomez DR. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer 22(3):225-233, 2021. e-Pub 2021. PMID: 32727706.
116. Corsini EM, Mitchell KG, Zhou N, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Maru DM, Lin SH, Ajani JA, Hofstetter WL. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg 111(4):1133-1140, 2021. e-Pub 2021. PMID: 32857997.
117. Ebrahimi S, Lim G, Liu A, Lin SH, Ellsworth SG, Grassberger C, Mohan R, Cao W. Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients. Int J Part Ther 8(2):17-27, 2021. e-Pub 2021.
118. Flint DB, Bright SJ, McFadden CH, Konishi T, Ohsawa D, Turner B, Lin SH, Grosshans DR, Chiu HS, Sumazin P, Shaitelman SF, Sawakuchi GO. Cell lines of the same anatomic site and histologic type show large variability in intrinsic radiosensitivity and relative biological effectiveness to protons and carbon ions. Med Phys, 2021. e-Pub 2021. PMID: 33837540.
119. Jing Y, Zhang Y, Wang J, Li K, Chen X, Heng J, Gao Q, Ye Y, Zhang Z, Liu Y, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. J Natl Cancer Inst, 2021. e-Pub 2021.
120. Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol 28:54-61, 2021. e-Pub 2021.
121. Rasing MJA, Peters M, Moreno AC, Hofman EFN, Herder GJM, Welvaart PWN, FMNH S, Lodeweges JE, Lin SH, Verhoeff JJC, van Rossum PSN. Predicting incomplete resection in non-small cell lung cancer preoperatively: a validated nomogram. Ann Thorac Surg 111(3):1052-1058, 2021. e-Pub 2021. PMID: 32739254.
122. Mohan R, Liu AY, Brown PD, Mahajan A, Dinh J, Chung C, McAvoy S, McAleer MF, Lin SH, Li J, Ghia AJ, Zhu C, Sulman EP, de Groot JF, Heimberger AB, McGovern SL, Grassberger C, Shih H, Ellsworth S, Grosshans DR. Proton Therapy Reduces the Likelihood of High-Grade Radiation-Induced Lymphopenia in Glioblastoma Patients: Phase II Randomized Study of Protons vs. Photons. Neuro Oncol 23(2):284-29, 2021. e-Pub 2021. PMID: 32750703.
123. Boyce-Fappiano D, Nguyen QN, Chapman BV, Allen PK, Gjyshi O, Pezzi TA, De B, Gomez D, Lin SH, Chang JY, Liao Z, Lee P, Gandhi SJ. Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer. Clin Lung Cancer, 2021. e-Pub 2021. PMID: 33707003.
124. Xie X, Lin SH, Welsh JW, Wei X, Jin H, Mohan R, Liao Z, Xu T. Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiother Oncol 154:187-193, 2021. e-Pub 2021.
125. De B, Ng SP, Liu AY, Avila S, Tao R, Holliday EB, Brownlee Z, Kaseb A, Lee S, Raghav K, Vauthey JN, Minsky BD, Herman JM, Das P, Smith GL, Taniguchi CM, Krishnan S, Crane CH, Grassberger C, Hong TS, Lin SH, Koong AC, Mohan R, Koay EJ. Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma 8:57-69, 2021. e-Pub 2021. PMID: 33688489.
126. Abe RJ, Savage H, Imanishi M, Banerjee P, Kotla S, Paez-Mayorga J, Taunton J, Fujiwara K, Won JH, Yusuf SW, Palaskas NL, Banchs J, Lin SH, Schadler KL, Abe JI, Le NT. Corrigendum: p90RSK-MAGI1 Module Controls Endothelial Permeability by Post-translational Modifications of MAGI1 and Hippo Pathway. Front Cardiovasc Med 8:663486, 2021. e-Pub 2021. PMID: 33681312.
127. Liang W, Cai K, Chen C, Chen H, Chen Q, Fu J, Hu J, Jiang T, Jiao W, Li S, Liu C, Liu D, Liu W, Liu Y, Ma H, Pan X, Qiao G, Tian H, Wei L, Zhang Y, Zhao S, Zhao X, Zhou C, Zhu Y, Zhong R, Li F, Rosell R, Provencio M, Massarelli E, Antonoff MB, Hida T, de Perrot M, Lin SH, Di Maio M, Rossi A, De Ruysscher D, Ramirez RA, Dempke WCM, Camidge DR, Guibert N, Califano R, Wang Q, Ren S, Zhou C, He J. Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 9(6):2696-2715, 2020. e-Pub 2020.
128. Ohannesian N, Misbah I, SH L, Shih WC. Plasmonic nano-aperture label-free imaging (PANORAMA). Nat Commun 16(11):505, 2020. e-Pub 2020. PMID: 33199716.
129. Gironda DJ, Adams DL, He J, Xu T, Gao H, Qiao Y, Komaki R, Reuben JM, Liao Z, Blum-Murphy M, Hofstetter WL, Tang CM, Lin SH. Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy. J Transl Med 18(1):413, 2020. e-Pub 2020. PMID: 33148307.
130. Cohen EN, Jayachandran G, Gao H, Qiao W, Liu S, Je J, Qiao Y, Yao L, Lin SH, Reuben JM. Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients. Transl Lung Cancer Res 9(5):1974-1985, 2020. e-Pub 2020. PMID: 33209617.
131. WSME T, Chen D, Verma V, Hobbs BP, Peulen HMU, JGJV A, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med, 2020. e-Pub 2020.
132. Verma V, Lin SH. Optimizing current standard f care therapy for stage III non-small cell lung cancer. Transl Lung Cancer Res 9(5):2033-2039, 2020. e-Pub 2020. PMID: 33209623.
133. Verma V, Ludmir EB, Mesko SM, Brooks ED, Augustyn A, Milano MT, Lin SH, Chang JY, Welsh JW. Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. Pract Radiat Oncol 10(5):324-329, 2020. e-Pub 2020.
134. Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, Yang Y, Diao L, Lin SH, Mills GB, Zhuang G, Xue X, Han L. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun 11(1):4946, 2020. e-Pub 2020. PMID: 33009409.
135. Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, Lin SH, Heymach JV. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33051340.
136. Li QW, QiuB, Liang WH, Wang JY, Hu WM, Zhang T, Xu SB, Lopez J, Chen NB, Guo MZ, Zhao Y, Chen LJ, Liu SR Yun JP, Guo JY Wang SY, Wang X, Zhang L, Yue DS, Liao ZX, SH L, Long H, Pang QS, Liu H. Risk prediction for locoregional recurrence in epidermal growth factor receptor-mutant stage III pN2 lung adenocarcinoma after complete resection: A multi-center retrospective study. J Cancer 11(20):6114-6121, 2020. e-Pub 2020. PMID: 32922551.
137. Corsini EM, Foo WC, Mitchell KG, Zhou N, Maru DM, Ajani JA, Hofstetter WL, Working Group EA, Correa AM, Antonoff MB, Lin SH, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg, 2020. e-Pub 2020. PMID: 33010880.
138. Xie X, Lin SH, Welsh JW, Wei X, Jin H, Mohan R, Liao Z, Xu T. Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiother Oncol 154:187-193, 2020. e-Pub 2020. PMID: 32916236.
139. Yalamanchali A, Zhang H, Huang KC, Mohan R, Lin SH, Zhu C, Grossman SA, Jin JY, Ellsworth SG. Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies. Adv Radiat Oncol 6(1):100545, 2020. e-Pub 2020.
140. Milton DR, Lin SH, Hobbs BP. Comparing Radiation Modalities with Trimodality Therapy Using Total Toxicity Burden. Int J Radiat Oncol Biol Phys 107(5):1001-1005, 2020. e-Pub 2020.
141. Mesko S, Ning MS, Lakomy D, Verma V, Chang JY, O'Reilly M, Jeter MD, Gandhi SJ, Lin SH, Nguyen QN, Liao Z, Welsh J, Chen AB, Hahn S, Gomez DR. Thoracic radiation oncology clinical trial accrual and reasons for non-enrollment: results of a large, prospective, multi-year analysis. Int J Radiat Oncol Biol Phys 107(5):897-908, 2020. e-Pub 2020. PMID: 32360653.
142. Kumar S, Chmura S, Robinson C, Lin SH, Gadgeel SM, Donington J, Feliciano J, Stinchcombe TE, Werner-Wasik M, Edelman MJ, Moghanaki D. Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic. J Thorac Oncol 15(7):1137-1146, 2020. e-Pub 2020. PMID: 32360578.
143. Venkatesulu BP, Sharma A, Pollard-Larkin JM, Sadagopan R, Symons J, Neri S, Singh PK, Tailor R, Lin SH, Krishnan S. Author Correction: Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome. Sci Rep 10(1):11018, 2020. e-Pub 2020. PMID: 32601350.
144. Wang X, Palaskas NL, Yusuf SW, Abe JI, Lopez-Mattei J, Banchs J, Gladish GW, Lee P, Liao Z, Deswal A, Lin SH. Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. J Thorac Oncol, 2020. e-Pub 2020.
145. Ning MS, McAleer MF, Jeter MD, Minsky BD, Ghafar RA, Robinson IJ, Nitsch PL, Zaebst DJ, Todd SE, Nguyen J, Lin SH, Liao Z, Lee P, Gunn GB, Klopp AH, Dabaja BS, Nguyen QN, Chronowski GM, Bloom ES, Koong AC, Das P. Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. Radiother Oncol 148:252-257, 2020. e-Pub 2020. PMID: 32474129.
146. Samson P, Ning MS, Shaverdian N, Shepherd AF, Gomez DR, McGinnis GJ, Nitsch PL, Chmura S, O'Reilly MS, Lee P, Chang JY, Robinson C, Lin SH. Clinical and Radiographic Presentations of COVID-19 among Patients Receiving Radiation Therapy for Thoracic Malignancies. Adv Radiat Oncol, 2020. e-Pub 2020. PMID: 32395673.
147. Xu C, Jin JY, Zhang M, Liu A, Wang J, Mohan R, Kong FS, Lin SH. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol 146:180-186, 2020. e-Pub 2020.
148. Lin SH, Hobbs BP, Verma V, Tidwell RS, Smith GL, Lei X, Corsini EM, Mok I, Wei X, Yao L, Wang X, Komaki RU, Chang JY, Chun SG, Jeter MD, Hahn JM, Swisher SG, Ajani JA, Blum-Murphy M, Vaporciyan AA, Mehran RJ, Koong AC, Gandhi SJ, Hofstetter WL, Hong TS, Delaney TF, Liao Z, Mohan R. Randomized Phase IIB Trial of Proton Beam Therapy versus Intensity Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. J Clin Oncol 38(14):1569-1579, 2020. e-Pub 2020.
149. Liu Y, Fan J, Xu T, Ahmadinejad N, Hess K, Lin SH, Zhang J, Liu X, Liu L, Ning B, Liao Z, Hu TY. Extracellular vesicle tetraspanin-8 level predicts distant metastasis in non-small cell lung cancer after concurrent chemoradiation. Sci Adv 6(11):6162, 2020. e-Pub 2020. PMID: 32195353.
150. Borggreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JJW, MGEH L, ALHMW VL, Mook S, Ruurda JP, van Vulpen M, Voncken FEM, Aleman BMP, Bartels-Rutten A, Ma J, Fang P, Musall BC, SH L, Meijer GJ. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study. Int J Radiat Oncol Biol Phys 106(5):998-1009, 2020. e-Pub 2020. PMID: 31987972.
151. Pezzi TA, Fang P, Gjyshi O, Feng L, Liu S, Komaki R, Lin SH. Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation. JAMA Netw Open 3(4):e201929, 2020. e-Pub 2020. PMID: 32236532.
152. Deng W, Jethwa KR, Gonuguntla K, Liao Z, Yoon HH, Murphy MB, Haddock MG, Hallemeier CL, Lin SH. Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. Adv Radiat Oncol 5(5):951-958, 2020. e-Pub 2020.
153. Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, Liu CL, Hui AB, Jin MC, Azad TD, Almanza D, Jeon YJ, Nesselbush MC, Co Ting Keh L, Bonilla RF, Yoo CH, Ko RB, Chen EL, Merriott DJ, Massion PP, Mansfield AS, Jen J, Ren HZ, Lin SH, Costantino CL, Burr R, Tibshirani R, Gambhir SS, Berry GJ, Jensen KC, West RB, Neal JW, Wakelee HA, Jr LB, Kunder CA, Leung AN, Lui NS, Berry MF, Shrager JB, Nair VS, Haber DA, Sequist LV, Alizadeh AA, Diehn M. Integrating genomic features for non-invasive early lung cancer detection. Nature 580(7802):245-251, 2020. e-Pub 2020.
154. Chun SG, Liao Z, Jeter MD, Chang JY, Lin SH, Komaki RU, Guerrero TM, Mayo RC, Korah BM, Koshy SM, Heymach JV, Koong AC, Skinner HD. Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial. Am J Clin Oncol 43(4):232-235, 2020. e-Pub 2020.
155. Yang L, Shen C, Pettit CJ, Li T, Hu AJ, Miller ED, Zhang J, Lin SH, Williams TM. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy. Clin Cancer Res, 2020. e-Pub 2020. PMID: 32220892.
156. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020.
157. Zhu C, Lin SH, Jiang X, Xiang Y, Belal Z, Jun G, Mohan R. A novel deep learning model using dosimetric and clinical information for grade 4 radiotherapy-induced lymphopenia prediction. Phys Med Biol 65(3):035014, 2020. e-Pub 2020. PMID: 31851954.
158. Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin SH, Ajani JA, Xiao Q, Liao Z, Wang H, Gan B. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res, 2020. e-Pub 2020.
159. Borggreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JJW, MGEH L, ALHMW VL, Mook S, Ruurda JP, van Vulpen M, Voncken FEM, Aleman BMP, Bartels-Rutten A, Ma J, Fang P, Musall BC, Lin SH, Meijer GJ. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study. Int J Radiat Oncol Biol Phys 106(5):998-1009, 2020. e-Pub 2020.
160. Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, Jones CD, He J, Qiao Y, Xu T, Heymach JV, Tsao A, Liao Z, Gomez GR, Das M, Padda SK, Ramchandran KJ, Neal JW, Wakelee HA, Loo BW, Lin SH, Alizadeh AA, Diehn M. 'Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nat Cancer, 2020. e-Pub 2020.
161. Pataer A, Ozpolat B, Shao R, Cashman NR, Plotkin SS, Samuel CE, Lin SH, Kabil NN, Wang J, Majidi M, Fang B, Roth JA, Vaporciyan AA, Wistuba II, Hung MC, Swisher SG. Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene 39(4):801-813, 2020. e-Pub 2020.
162. Moreno AC, Fellman B, Hobbs BP, Liao Z, Gomez DR, Chen A, Hahn SM, Chang JY, Lin SH. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer. J Thorac Oncol 15(1):101-109, 2020. e-Pub 2020.
163. van Rossum PSN, Deng W, Routman DM, Liu AY, Xu C, Shiraishi Y, Peters M, Merrell KW, Hallemeier CL, Mohan R, Lin SH. Prediction of severe lymphopenia during chemoradiotherapy for esophageal cancer: development and validation of a pretreatment nomogram. Pract Radiat Oncol 10(1):16-26, 2020. e-Pub 2020. PMID: 31369887.
164. Abe RJ, Savage H, Imanishi M, Banerjee P, Kotla S, Paez-Mayorga J, Taunton J, Fujiwara K, Won JH, Yusuf SW, Palaskas NL, Banchs J, Lin SH, Schadler KL, Abe JI, Le NT. p90RSK-MAGI1 Module Controls Endothelial Permeability by Post-translational Modifications of MAGI1 and Hippo Pathway. Front Cardiovasc Med 7:542485, 2020. e-Pub 2020. PMID: 33304925.
165. Thomas M, Defraene G, Lambrecht M, Deng W, Moons J, Nafteux P, Lin SH, Haustermans K. NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiother Oncol 141:33-40, 2019. e-Pub 2019.
166. Veeranki OL, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, Kim TB, Wang J, Lang W, Mino B, Solis L, Kingsley C, Norton W, Tailor R, Wu JY, Krishnan S, Lin SH, Blum M, Hofstetter W, Ajani J, Kopetz S, Maru D. A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. Dis Model Mech 12(12), 2019. e-Pub 2019.
167. Venkatesulu BP, Sharma A, Pollard-Larkin JM, Sadagopan R, Symons J, Neri S, Singh PK, Tailor R, Lin SH, Krishnan S. Ultra high dose rate (35 Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome. Sci Rep 9(1):17180, 2019. e-Pub 2019.
168. Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, Hamilton EG, Yang YD, Lovejoy A, Newman AM, Kurtz DM, Jin M, Schroers-Martin J, Stehr H, Liu CL, Hui AB, Patel V, Maru D, Lin SH, Alizadeh AA, Diehn M. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology, 2019. e-Pub 2019.
169. Milgrom SA, Varghese B, Gladish GW, Choi AD, Dong W, Patel ZS, Chung CC, Rao A, Pinnix CC, Gunther JR, Dabaja BS, Lin SH, Hoffman KE, Huff JL, Slagowski J, Abe JI, Iliescu CA, Banchs J, Yusuf SW, Lopez-Mattei JC. Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. J Cardiovasc Imaging 27(4):268-279, 2019. e-Pub 2019.
170. Thomas M, Borggreve AS, van Rossum PSN, Perneel C, Moons J, Van Daele E, van Hillegersberg R, Deng W, Pattyn P, Mook S, Boterberg T, Ruurda JP, Nafteux P, Lin SH, Haustermans K. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis. Acta Oncol 58(10):1358-1365, 2019. e-Pub 2019.
171. Li N, Wang Y, Neri S, Zhen Y, Fong LW, Qiao Y, Li X, Chen Z, Stephan C, Deng W, Ye R, Jiang W, Zhang S, Yu Y, Hung MC, Chen J, Lin SH. Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. Nat Commun 10(1):4363, 2019. e-Pub 2019.
172. Meraz IM, Majidi M, Meng F, Shao R, Ha MJ, Neri S, Fang B, Lin SH, Tinkey PT, Shpall EJ, Morris J, Roth JA. An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunol Res 7(8):1267-1279, 2019. e-Pub 2019. PMID: 31186248.
173. Gjyshi O, Ludmir EB, Pezzi TA, Boyce-Fappiano D, Dursteler AE, Mitin T, Lin SH. Evolving Practice Patterns in the Use of Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer. JAMA Netw Open 2(8):e199135, 2019. e-Pub 2019.
174. Lin SH. The Role of Adjuvant Radiotherapy for Resected Non-Small Cell Lung Cancer in the Modern Era. Int J Radiat Oncol Biol Phys 104(4):712-713, 2019. e-Pub 2019. PMID: 31204657.
175. Xu C, Guo L, Liao Z, Wang Y, Liu X, Zhao S, Wang J, Yuan Z, Wang P, Lin SH. Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. Clin Transl Radiat Oncol 17:17-23, 2019. e-Pub 2019. PMID: 31080898.
176. Veeranki OL, Tong Z, Dokey R, Mejia A, Zhang J, Qiao Y, Singh PK, Katkhuda R, Mino B, Tailor R, Canales JR, Bassett R, Ajani J, Wu JY, Kopetz S, Blum M, Hofstetter W, Tetzlaff M, Krishnan S, Lin SH, Maru D. Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. Oncotarget 10(45):4703-4718, 2019. e-Pub 2019. PMID: 31384397.
177. Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Mandel JJ, Lin SH, Smith BD, Smith GL, VanderWalde NA, Minsky BD, Koong AC, Stinchcombe TE, Jagsi R, Gomez DR, Thomas CR, Fuller CD. Factors Associated With Age Disparities Among Cancer Clinical Trial Participants. JAMA Oncol, 2019. e-Pub 2019. PMID: 31158272.
178. Deng W, Xu C, Liu A, van Rossum PSN, Deng W, Liao Z, Koong AC, Mohan R, Lin SH. The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. Radiother Oncol 133:9-15, 2019. e-Pub 2019. PMID: 30935587.
179. Moreno AC, Zhang N, Verma V, Giordano, Lin SH. Treatment disparities affect outcomes for patients with stage I esophageal cancer: a national cancer data base analysis. J Gastrointest Oncol 10(1):74-84, 2019. e-Pub 2019. PMID: 30788162.
180. Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM. Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. Ther Adv Med Oncol 11:1758835919864850, 2019. e-Pub 2019. PMID: 31384313.
181. Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH. Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis. Radiat Oncol 13(1):258-263, 2018. e-Pub 2018. PMID: 30594213.
182. Tao R, Ager B, Lloyd S, Torgeson A, Denney M, Gaffney D, Kharofa J, Lin SH, Koong AC, Anzai Y, Hoffman JM. Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy. J Gastrointest Oncol 9(6):1044-1053, 2018. e-Pub 2018. PMID: 30603123.
183. Li N, Wang Y, Deng W, Lin SH. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. Anticancer Agents Med Chem, 2018. e-Pub 2018. PMID: 30417796.
184. Suzuki R, Wei X, Allen PK, Cox JD, Komaki R, Lin SH. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer. Clin Lung Cancer, 2018. e-Pub 2018. PMID: 30611672.
185. Goense L, Lin SH. ASO Author Reflections: Predicting Early Recurrence After Trimodality Therapy for Esophageal Adenocarcinoma. Ann Surg Oncol, 2018. e-Pub 2018. PMID: 30443832.
186. Fang P, Shiraishi Y, Verma V, Jiang W, Song J, Hobbs BP, Lin SH. Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation. Int J Part Ther 4(3):23-32, 2018. e-Pub 2018. PMID: 30079369.
187. No HJ, Lester-Coll NH, Seward DJ, Sidiropoulos N, Gagne HM, Nelson CJ, Garrison GW, Kinsey CM, Lin SH, Anker CJ. Active Surveillance for Medically Inoperable Stage IA Lung Cancer in the Elderly. Cureus 10(10):3472, 2018. e-Pub 2018. PMID: 30648024.
188. Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 124(18):3693-3705, 2018. e-Pub 2018. PMID: 30289966.
189. Zhou S, Liu S, Zhang L, Guo S, Shen J, Li Q, Yang H, Feng Y, Liu M, Lin SH, Xi M. Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance Strategies. Ann Surg Oncol, 2018. e-Pub 2018. PMID: 30194608.
190. Moreno AC, Zhang N, Giordano SH, Liao Z, Gomez D, Chang JY, Lin SH. Trends and Outcomes of Proton Radiation Therapy Use for Non-Small Cell Lung Cancer. Int J Part Ther 5(2):18-27, 2018. e-Pub 2018.
191. Suzuki R, Wei X, Allen PK, Welsh JW, Komaki R, Lin SH. Hematologic variables associated with brain failure in patients with small-cell lung cancer. Radiother Oncol 128(3):505-512, 2018. e-Pub 2018. PMID: 29907337.
192. Goense L, Ruurda JP, Carter BW, Fang P, Ho L, Meijer GJ, van Hillegersberg R, Hofstetter WL, Lin SH. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 45(10):1742-1751, 2018. e-Pub 2018. PMID: 29663014.
193. Fang P, Jiang W, Davuluri R, Xu C, Krishnan S, Mohan R, Koong AC, Hsu CC, Lin SH. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. Radiother Oncol 128(3):584-590, 2018. e-Pub 2018. PMID: 29530432.
194. Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, Ajani JA, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Ann Surg 268(2):289-295, 2018. e-Pub 2018. PMID: 28628563.
195. Suzuki R, Wei X, Allen PK, Welsh JW, Cox JD, Komaki R, Lin SH. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis. Clin Lung Cancer, 2018. e-Pub 2018. PMID: 30197263.
196. Wang Y, Li N, Jiang W, Deng W, Ye R, Xu C, Qiao Y, Sharma A, Zhang M, Hung MC, Lin SH. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res, 2018. e-Pub 2018. PMID: 30068711.
197. Nantavithya C, Gomez DR, Wei X, Komaki R, Liao Z, Lin SH, Jeter M, Nguyen QN, Li H, Zhang X, Poenisch F, Zhu XR, Balter PA, Feng L, Choi NC, Mohan R, Chang JY. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 101(3):558-563, 2018. e-Pub 2018. PMID: 29680255.
198. Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol 128(1):154-160, 2018. e-Pub 2018. PMID: 29248170.
199. Goense L, Merrell KW, Arnett AL, Hallemeier CL, Meijer GJ, Ruurda JP, Hofstetter WL, van Hillegersberg R, Lin SH. Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer. Ann Thorac Surg, 2018. e-Pub 2018. PMID: 29932887.
200. Goense L, van Rossum PSN, Xi M, Maru DM, Carter BW, Meijer GJ, Ho L, van Hillegersberg R, Hofstetter WL, Lin SH. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. Ann Surg Oncol 25(6):1598-1607, 2018. e-Pub 2018. PMID: 29569125.
201. Verma V, Moreno AC, Haque W, Fang P, Lin SH. Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non-Small Cell Lung Cancer. J Natl Compr Canc Netw 16(5):508-516, 2018. e-Pub 2018. PMID: 29752325.
202. Zheng X, Fang Z, Liu X, Deng S, Zhou P, Wang X, Zhang C, Yin R, Hu H, Chen X, Han Y, Zhao Y, Lin SH, Qin S, Wang X, Kim BY, Zhou P, Jiang W, Wu Q, Huang Y. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J Clin Invest 128(5):2104-2115, 2018. e-Pub 2018. PMID: 29664018.
203. Moreno AC, Haque W, Verma V, Fang P, Lin SH. Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base. Ann Surg Oncol 25(5):1245-1253, 2018. e-Pub 2018. PMID: 29484562.
204. McGrail DJ, Federico L, Li Y, Dai H, Lu Y, Mills GB, Yi S, Lin SH, Sahni N. Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9(1):1317, 2018. e-Pub 2018. PMID: 29615613.
205. Prayongrat A, Umegaki K, van der Schaaf A, Koong AC, Lin SH, Whitaker T, McNutt T, Matsufuji N, Graves E, Mizuta M, Ogawa K, Date H, Moriwaki K, Ito YM, Kobashi K, Dekura Y, Shimizu S, Shirato H. Present developments in reaching an international consensus for a model-based approach to particle beam therapy. J Radiat Res 59(suppl_1):i72-i76, 2018. e-Pub 2018. PMID: 29529229.
206. Fang P, Musall BC, Son JB, Moreno AC, Hobbs BP, Carter BW, Fellman BM, Mawlawi O, Ma J, Lin SH. Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer. Int J Radiat Oncol Biol Phys, 2018. e-Pub 2018. PMID: 29685377.
207. Barua S, Fang P, Sharma A, Fujimoto J, Wistuba I, Rao AUK, Lin SH. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. Lung Cancer, 2018. e-Pub 2018.
208. Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, Komaki R. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol, 2018. e-Pub 2018.
209. Goense L, Heethuis SE, van Rossum PSN, Voncken FEM, Lagendijk JJW, MGEH L, Terhaard CH, van Hillegersberg R, Ruurda JP, Mook S, ALHMW VL, Lin SH, Meijer GJ. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer. Nucl Med Commun 39(1):60-67, 2018. e-Pub 2018. PMID: 29023336.
210. Lin SH, Koong AC. Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer. J Natl Cancer Inst 110(1), 2018. e-Pub 2018. PMID: 28922792.
211. Xi M, Yang Y, Zhang L, Yang H, Merrell KW, Hallemeier CL, Shen RK, Haddock MG, Hofstetter WL, Maru DM, Ho L, Wu CC, Liu M, Lin SH. Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer: Impact of Histology on Recurrence Patterns and Outcomes. Ann Surg, 2018. e-Pub 2018. PMID: 29334555.
212. Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. (18)F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. J Nucl Med 58(11):1756-1763, 2017. e-Pub 2017. PMID: 28522744.
213. Verma V, Allen PK, Simone CB, Gay HA, Lin SH. Association of Treatment at High-Volume Facilities With Survival in Patients Receiving Chemoradiotherapy for Nasopharyngeal Cancer. JAMA Otolaryngol Head Neck Surg, 2017. e-Pub 2017. PMID: 29098291.
214. Xi M, Yang Y, Zhang L, Yang H, Merrell KW, Hallemeier CL, Shen RK, Haddock MG, Hofstetter WL, Maru DM, Ho L, Wu CC, Liu M, Lin SH, . Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: The impact of histology on recurrence patterns and outcomes. Ann Surg 99(3):667-676, 2017. e-Pub 2017.
215. Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, Ajani JA. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer 123(21):4106-4113, 2017. e-Pub 2017. PMID: 28885712.
216. Xi M, Xu C, Liao Z, Chang JY, Gomez DR, Jeter M, Cox JD, Komaki R, Mehran R, Blum-Murphy M, Hofstetter WL, Maru DM, Bhutani MS, Lee JH, Weston B, Ajani AA, Lin SH, . Comparative Outcomes after Definitive Chemoradiotherapy using Proton Beam Therapy versus Intensity-Modulated Radiation Therapy for Esophageal Cancer: A Retrospective Single-Institutional Analysis. Int J Radiat Oncol Biol Phys 99(3):667-676, 2017. e-Pub 2017.
217. Verma V, Allen PK, Simone CB, Gay HA, Lin SH. Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer. J Natl Compr Canc Netw 15(11):1383-1391, 2017. e-Pub 2017. PMID: 29118230.
218. An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, Lin SH, Yu JB, Davies MA, Hwu P, Sulman EP, Brown PD, Chiang VLS, Li J. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80-88, 2017. e-Pub 2017. PMID: 28916225.
219. Xi M, Lin SH. Prognostic and Predictive Value of FDG-PET as an Aid in Oesophageal Cancer Management. European Medical Journal:78-84, 2017. e-Pub 2017.
220. Wang Y, Gudikote J, Giri U, Yan J, Deng W, Ye R, Jiang W, Li N, Hobbs B, Wang J, Swisher SG, Fujimoto J, Wistuba II, Komaki R, Heymach J, Lin SH. RAD50 expression is associated with poor clinical outcomes after radiotherapy for resected non-small cell lung cancer. Clin Cancer Res, 2017. e-Pub 2017. PMID: 29030353.
221. Adams DL, Adams DK, He J, Kalhor N, Zhang M, Xu T, Gao H, Reuben JM, Qiao Y, Komaki R, Liao Z, Edelman MJ, Tang CM, Lin SH. Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy. Clin Cancer Res 23(19):5948-5958, 2017. e-Pub 2017. PMID: 28679765.
222. Goense L, Heethuis SE, van Rossum PSN, Voncken FEM, Lagendijk JJW, MGEH L, Terhaard CH, van Hillegersberg R, Ruurda JP, Mook S, ALHMW VL, Lin SH, Meijer GJ. Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer. Nucl Med Commun, 2017. e-Pub 2017. PMID: 29023336.
223. Shiraishi Y, Xu C, Yang J, Komaki R, Lin SH. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Radiother Oncol 125(1):48-54, 2017. e-Pub 2017. PMID: 28917586.
224. Xi M, Liao Z, Deng W, Komaki R, Ho L, Lin SH. Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. Int J Radiat Oncol Biol Phys 99(2):407-416, 2017. e-Pub 2017. PMID: 28871991.
225. Zhao L, Zhou Y, Pan H, Yin Y, Chai G, Mu Y, Xiao F, Lin SH, Shi M. Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients. J Cancer 8(16):3242-3250, 2017. e-Pub 2017.
226. Prayongrat A, Xu C, Li H, Lin SH, . Clinical outcomes of intensity-modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. Advances in Radiation Oncology 2(301-307), 2017. e-Pub 2017.
227. Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, Spigel DR, Strawn JR, Ung YC, Weyant M. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin Oncol 35(25):2960-2974, 2017. e-Pub 2017. PMID: 28437162.
228. Davuluri R, Jiang W, Fang P, Xu C, Komaki R, Gomez DR, Welsh J, Cox JD, Crane CH, Hsu CC, Lin SH. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys 99(1):128-135, 2017. e-Pub 2017. PMID: 28816138.
229. Xi, M, Xu, C, Liao, Z, Hofstetter, WL, Blum Murphy, M, Maru, DM, Bhutani, M, Lee, JH, Weston, B, Komaki, R, Lin, SH. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiotherapy and Oncology 124(2):318-324, 2017. e-Pub 2017. PMID: 28687396.
230. Kono M, Allen PK, Lin SH, Wei X, Jeter M, Welsh JW, Cox JD, Komaki R. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. J Thorac Oncol, 2017. e-Pub 2017.
231. Chapple AG, Vannucci M, Thall PF, Lin SH. Bayesian variable selection for a semi-competing risks model with three hazard functions. Comput Stat Data Anal 112:170-185, 2017. e-Pub 2017. PMID: 29033478.
232. Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JD. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol, 2017. e-Pub 2017.
233. Verma V, Simone CB, Krishnan S, Lin SH, Yang J, Hahn SM. The Rise of Radiomics and Implications for Oncologic Management. J Natl Cancer Inst 109(7):1-3, 2017. e-Pub 2017. PMID: 28423406.
234. Xu C, Xi M, Moreno A, Shiraishi Y, Hobbs BP, Huang M, Komaki R, Lin SH. Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old. Int J Radiat Oncol Biol Phys 98(4):811-819, 2017. e-Pub 2017. PMID: 28602412.
235. Lester SC, Lin SH, Chuong M, Bhooshan N, Liao Z, Arnett AL, James SE, Evans JD, Spears GM, Komaki R, Haddock MG, Mehta MP, Hallemeier CL, Merrell KW. A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. Int J Radiat Oncol Biol Phys 98(4):820-828, 2017. e-Pub 2017. PMID: 28476435.
236. Xu C, Lin SH. Deciding on the neoadjuvant approach for esophageal adenocarcinomas. J Thorac Dis 9(7):1818-1821, 2017. e-Pub 2017.
237. Xi M, Lin SH. Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer. Expert Rev Anticancer Ther 17(7):635-646, 2017. e-Pub 2017.
238. Ho JC, Nguyen QN, Li H, Allen PK, Zhang X, Liao Z, Zhu XR, Gomez D, Lin SH, Gillin M, Komaki R, Hahn S, Chang JY. Reirradiation of Thoracic Cancers with Intensity Modulated Proton Therapy. Pract Radiat Oncol, 2017. e-Pub 2017. PMID: 28867546.
239. Xu C, Xi M, Moreno A, Shiraishi Y, Hobbs B, Huang M, Komaki R, Lin SH. Clinical Outcomes of elderly patients with esophageal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 98(4):811-819, 2017. e-Pub 2017.
240. Moreno AC, Verma V, Hofstetter WL, Lin SH. Patterns of Care and Treatment Outcomes of Elderly Patients With Stage I Esophageal Cancer: Analysis of the National Cancer Data Base. J Thorac Oncol 12(7):1152-1160, 2017. e-Pub 2017.
241. Lin SH, Merrell KW, Shen J, Verma V, Correa AM, Wang L, Thall PF, Bhooshan N, James SE, Haddock MG, Suntharalingam M, Mehta M, Liao Z, Cox JD, Komaki R, Mehran R, Chuong MD, Hallemeier CL. Multi-institutional Analysis of Radiation Modality Use and Postoperative Outcomes of Neoadjuvant Chemoradiation for Esophageal Cancer. Radiother Oncol 123(3):376-381, 2017. e-Pub 2017.
242. Xi M, Liao Z, Hofstetter WL, Komaki R, Ho L, Lin SH. Positron Emission Tomography Response After Induction Chemotherapy Can Predict Who Will Benefit From Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Cancer. J Nucl Med, 2017. e-Pub 2017.
243. No H, Kikut J, Garrison G, Sidiropoulos N, Leavitt B, Gentchos G, Lin SH, , Anker CJ. Active Surveillance for Elderly Stage IA Non-Small Cell Lung Cancer Patients. Int J Radiat Oncol Biol Phys 98(1):232, 2017. e-Pub 2017.
244. Fang P, Swanick CW, Pezzi TA, Liao Z, Welsh J, Lin SH, Gomez DR. Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer. Pract Radiat Oncol, 2017. e-Pub 2017.
245. Lan M, Xu T, Gomez DR, Jeter MD, Nguyen QN, Deng W, Lin SH, Komaki RU, Liao Z. Association Between LGALS3 Gene Polymorphisms and Survival in Non-Small Cell Lung Cancer Patients Treated With Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 98(1):249-250, 2017. e-Pub 2017.
246. Shi A, Liao Z, Allen PK, Ho L, Murphy M, Maru DM, Swisher SG, Hofstetter WL, Mehran RJ, Cox JD, Komaki R, Lin SH. Long Term Survival and Toxicity Outcomes of Intensity-Modulated Radiation Therapy for the Treatment of Esophageal Cancer: A Large Single-Institutional Cohort Study. Advances in Radiation Oncology 2:316-324, 2017. e-Pub 2017.
247. Tong Z, Chatterjee D, Deng D, Veeranki O, Mejia A, Ajani JA, Hofstetter W, Lin SH, Guha S, Kopetz S, Krishnan S, Maru D. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget 8(17):28696-28710, 2017. e-Pub 2017. PMID: 28404924.
248. Liu S, Anfossi S, Qiu B, Zheng Y, Cai M, Fu J, Yang H, Liu Q, Chen Z, Fu J, Liu M, Burks JK, Lin SH, Reuben J, Liu H. Prognostic Factors for Locoregional Recurrence in Patients with Thoracic Esophageal Squamous Cell Carcinoma Treated with Radical Two-Field Lymph Node Dissection: Results from Long-Term Follow-Up. Ann Surg Oncol 24(4):966-973, 2017. e-Pub 2017.
249. Xu C, Xi M, Komaki R, Balter PA, Huang M, Hobbs BP, Wang L, Lin SH. Dosimetric and Clinical Outcomes After Volumetric Modulated arc Therapy for Carcinoma of the Thoracic Esophagus. Advances in Radiation Oncology 2:325-332, 2017. e-Pub 2017.
250. Logan JK, Tang C, Liao Z, Lee JJ, Heymach JV, Swisher SG, Welsh JW, Zhang J, Lin SH, Gomez DR. Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. Int J Radiat Oncol Biol Phys 97(4):770-777, 2017. e-Pub 2017. PMID: 28244413.
251. Verma V, 2nd SC, Allen PK, Lin SH. Outcomes of Stereotactic Body Radiotherapy for T1-T2N0 Small Cell Carcinoma According to Addition of Chemotherapy and Prophylactic Cranial Irradiation: A Multicenter Analysis. Clin Lung Cancer, 2017. e-Pub 2017. PMID: 28408183.
252. Xi M, Liao Z, Deng W, Xu C, Komaki R, Blum M, Hofstetter WL, Ho L, Lin SH. A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. J Thorac Oncol, 2017. e-Pub 2017.
253. Zhao L, Zhou Y, Mu Y, Chai G, Xiao F, Tan L, Lin SH, , Shi M. Patterns of failure and clinical outcomes of definitive radiotherapy for cervical esophageal cancer. Oncotarget 8(13):21852-21860, 2017. e-Pub 2017.
254. Verma V, Simone CB, Allen PK, Gajjar SR, Shah C, Zhen W, Harkenrider MM, Hallemeier CL, Jabbour SK, Matthiesen CL, Braunstein SE, Lee P, Dilling TJ, Allen BG, Nichols EM, Attia A, Zeng J, Biswas T, Paximadis P, Wang F, Walker JM, Stahl JM, Daly ME, Decker RH, Hales RK, Willers H, Videtic GMM, Mehta MP, Lin SH, . Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 97(2):362-371, 2017. e-Pub 2017. PMID: 28011047.
255. Swanick CW, Allen PK, Tao R, Olanrewaju AM, Sutton JR, Lin SH, Welsh J, Das P, Chang JY, Crane CH, Gomez DR. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Pract Radiat Oncol 7(1):63-71, 2017. e-Pub 2017.
256. van Rossum PS, Fried DV, Zhang L, Hofstetter WL, Ho L, Meijer GJ, Carter BW, Court LE, Lin SH. The value of (18)F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. Eur J Nucl Med Mol Imaging 44(1):71-80, 2017. e-Pub 2017. PMID: 27511188.
257. Verma V, Allen PK, Lin SH. Evaluating Factors for Prophylactic Feeding Tube Placement in Gastroesophageal Cancer Patients Undergoing Chemoradiotherapy. Front Oncol 7:235, 2017. e-Pub 2017. PMID: 29021972.
258. Wang Y, Liu H, Diao L, Potter A, Zhang J, Qiao Y, Wang J, Proia DA, Tailor R, Komaki R, Lin SH, . Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Clin Cancer Res 22(23):5876-5886, 2016. e-Pub 2016. PMID: 27354472.
259. Verma V, Moreno AC, Lin SH, . Advances in Radiotherapy Management of Esophageal Cancer. J Clin Med 21(5):1-11, 2016. e-Pub 2016.
260. He L, Chapple A, Liao Z, Komaki R, Thall PF, Lin SH. Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. Radiother Oncol 121(1):70-74, 2016. e-Pub 2016. PMID: 27562616.
261. Wang L, Hoogcarspel SJ, Wen Z, van Vulpen M, Molkentine DP, Kok J, Lin SH, Broekhuizen R, Ang KK, Bovenschen N, Raaymakers BW, Frank SJ. Biological responses of human solid tumor cells to X-ray irradiation within a 1.5-Tesla magnetic field generated by a magnetic resonance imaging-linear accelerator. Bioelectromagnetics 37(7):471-480, 2016. e-Pub 2016.
262. Wang L, Hoogcarspel SJ, Wen Z, van Vulpen M, Molkentine DP, Kok J, Lin SH, Broekhuizen R, Ang KK, Bovenschen N, Raaymakers BW, Frank SJ. Biological responses of human solid tumor cells to X-ray irradiation within a 1.5-Tesla magnetic field generated by a magnetic resonance imaging-linear accelerator. Bioelectromagnetics 37(7):471-80, 2016. e-Pub 2016. PMID: 27434783.
263. Verma V, Lin SH, , 2nd SC, Mehta MP. Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. J Gastrointest Oncol 7(4):644-664, 2016. e-Pub 2016.
264. Lin SH, Hallemeier CL, Chuong M. Proton beam therapy for the treatment of esophageal cancer. Chin Clin Oncol 5(4):53, 2016. e-Pub 2016.
265. Zhao L, Zhou S, Balter P, Shen C, Gomez DR, Welsh JD, Lin SH, Chang JY. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 95(4):1226-1235, 2016. e-Pub 2016.
266. van Rossum PS, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, Court LE, Lin SH. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer. J Nucl Med 57(5):691-700, 2016. e-Pub 2016. PMID: 26795288.
267. Li N, Feng L, Liu H, Wang J, Kasembeli M, Tran MK, Tweardy DJ, Lin SH, Chen J. PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Rep, 2016. e-Pub 2016. PMID: 27149849.
268. Lin SH, Zhang N, Godby J, Wang J, Marsh GD, Liao Z, Komaki R, Ho L, Hofstetter WL, Swisher SG, Mehran RJ, Buchholz TA, Elting LS, Giordano SH. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer 122(6):917-928, 2016. e-Pub 2016. PMID: 26716915.
269. Yu J, Zhang X, Liao L, Li H, Zhu R, Park PC, Sahoo N, Gillin M, Li Y, Chang JY, Komaki R, Lin SH. Motion-robust intensity modulated proton therapy for distal esophageal cancer. Med Phys 43(3):1111, 2016. e-Pub 2016. PMID: 26936698.
270. Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage, 2016. e-Pub 2016. PMID: 26891607.
271. Hobbs BP, Thall PF, Lin SH. Bayesian Group Sequential Clinical Trial Design using Total Toxicity Burden and Progression-Free Survival. J R Stat Soc Ser C Appl Stat 65(2):273-297, 2016. e-Pub 2016. PMID: 27034510.
272. Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila) 8(11):1027-1035, 2015. e-Pub 2015. PMID: 26342026.
273. van Rossum PS, van Lier AL, van Vulpen M, Reerink O, Lagendijk JJ, Lin SH, van Hillegersberg R, Ruurda JP, Meijer GJ, Lips IM. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. Radiother Oncol 115(2):163-170, 2015. e-Pub 2015. PMID: 26002307.
274. Swanick CW, Lin SH, Sutton J, Naik NS, Allen PK, Levy LB, Liao Z, Welsh JW, Komaki R, Chang JY, Gomez DR. Use of Simultaneous Radiation Boost Achieves High Control Rates in Patients With Non-Small-Cell Lung Cancer Who Are Not Candidates for Surgery or Conventional Chemoradiation. Clin Lung Cancer 16(2):156-163, 2015. e-Pub 2015. PMID: 25467928.
275. Wang J, Milton DR, He L, Komaki R, Liao Z, Crane CH, Minsky BD, Thall PF, Lin SH. Comparison of Locoregional versus Extended Locoregional Radiation Volumes for Patients with Nonmetastatic Gastro-esophageal Junction Carcinomas. J Thorac Oncol 10(3):518-526, 2015. e-Pub 2015. PMID: 25695222.
276. Lin SH, Wang J, Allen PK, Correa AM, Maru D, Swisher SG, Hofstetter WL, Liao Z, Ajani JA. Nomogram for Pathologic Complete Response to Neoadjuvant Chemoradiation also Predicts Survival Outcomes after Definitive Chemoradiation for Esophageal Cancer. J Gastrointest Oncol 6(1):45-52, 2015. e-Pub 2015. PMID: 25642337.
277. Wang J, Palmer M, Bilton SD, Khoi VN, Greer S, Frame R, Liao Z, Komaki R, Cox JD, Lin SH. Comparing Proton Beam to Intensity Modulated Radiation Therapy Planning in Esophageal Cancer. Int J Particle Ther, 2015. e-Pub 2015.
278. Guan F, Bronk L, Titt U, Lin SH, Mirkovic D, Kerr MD, Zhu XR, Dinh J, Sobieski M, Stephan C, Peeler CR, Taleei R, Mohan R, Grosshans DR. Spatial mapping of the biologic effectiveness of scanned particle beams: towards biologically optimized particle therapy. Sci Rep 5(9850):1-10, 2015. e-Pub 2015. PMID: 25984967.
279. He LR, Qiao W, Liao ZX, Komaki R, Ho L, Hofstetter WL, Lin SH. Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer 15(111):1095, 2015. e-Pub 2015. PMID: 25777421.
280. Xu T, Liao Z, O'Reilly MS, Levy LB, Welsh JW, Wang LE, Lin SH, Komaki R, Liu Z, Wei Q, Gomez DR. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol 113(3):379-384, 2014. e-Pub 2014. PMID: 25466375.
281. Lin SH, Wang J, Saintigny P, WuCC, Giri U, Zhang J, Menju T, Diao L, Byers L, Weinstein JN, Coombes KR, Girard L, Komaki R, Wistuba II, Date H, Minna JD, Heymach JV. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics 15, 2014. e-Pub 2014. PMID: 25486910.
282. Gomez DR, Yusuf SW, Munsell MF, Welsh JW, Liao Z, Lin SH, Pan HY, Chang JY, Komaki R, Cox JD, McAleer MF, Grosshans DR. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol 9(10):1551-60, 2014. e-Pub 2014. PMID: 25521400.
283. Wang1 J, Court2 LE, Rao2 A, Bassett3 R, Lee1 JK, Hunter2 L, Myles1 B, Liao1 Z, and Lin SH. Textural Features on Computed Tomography Scans Predict Overall Survival in Patients with Esophageal Cancer. Nuclear Medicine & Radiation, 2014. e-Pub 2014.
284. He L, Allen PK, Potter A, Wang J, Chang JY, Gomez DR, Komaki R, Liao Z, Lin SH. Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. J Thorac Oncol 9(9):1398-1405, 2014. e-Pub 2014. PMID: 25122435.
285. Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, Ajani JA, Swisher SG, Maru DM. Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation. Ann Thorac Surg 98(3):1064-1071, 2014. e-Pub 2014. PMID: 25038008.
286. Lin SH, Zhang J, Giri U, Stephan C, Sobieski M, Zhong L, Mason KA, Molkentine J, Thames HD, Yoo SS, Heymach JV. A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non-Small Cell Lung Cancer. J Thorac Oncol 9(7):965-973, 2014. e-Pub 2014. PMID: 24922006.
287. Wang J, Suri JS, Allen PK, Liao Z, Komaki R, Ho L, Hofstetter WL, Lin SH. Factors Predictive of Improved Outcomes With Multimodality Local Therapy After Palliative Chemotherapy for Stage IV Esophageal Cancer. Am J Clin Oncol, 2014. e-Pub 2014. PMID: 24710122.
288. Juloori A, Tucker SL, Komaki R, Liao Z, Correa AM, Swisher SG, Hofstetter WL, Lin SH. Influence of preoperative radiation field on postoperative leak rates in Esophageal cancer patients after trimodality therapy. J Thorac Oncol 9(4):534-540, 2014. e-Pub 2014. PMID: 24736077.
289. Ly NB, Allen PK, Lin SH. Stereotactic body radiation therapy for stage I small cell lung cancer: a single institutional case series and review of the literature. J Radiat Oncol, 2014. e-Pub 2014.
290. Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, Ajani JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for Esophageal Carcinoma. Dis Esophagus 27(2):168-175, 2014. e-Pub 2014. PMID: 23621168.
291. Yang Y, Ahn YH, Chen Y, Tan X, Guo L, Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, Thilaganathan N, Wistuba II, Rodriguez-Canales J, McLendon G, Creighton CJ, Kurie JM. ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest 124:2696-2708, 2014. e-Pub 2014.
292. Zhang X, Lin SH, Fang B, Gillin M, Mohan R, Chang JY. Therapy resistant cancer stem cells have differing sensitivity to photon versus proton beam radiation. J Thorac Oncol 8(12):1484-1491, 2013. e-Pub 2013. PMID: 24389430.
293. Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 86(5):885-891, 2013. e-Pub 2013. PMID: 23845841.
294. Gomez DR, Gillin M, Liao Z, Wei C, Lin SH, Swanick C, Alvarado T, Komaki R, Cox JD, Chang JY. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 86(4):665-70, 2013. e-Pub 2013.
295. Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-1009, 2013. e-Pub 2013. PMID: 22950385.
296. Wu CC, Kannan K, Lin SH, Yen L, Milosavlijevic A. Identification of cancer fusion drivers using network fusion centrality. Bioinformatics, 2013. e-Pub 2013.
297. Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, Ajani JA. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol 24(5):1262-1266, 2013. e-Pub 2013. PMID: 23247658.
298. Lin SH, George T, Ben-Josef E, Bradley J, Choe K, Edelman MJ, Guha C, Krishnan S, Lawrence T, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman N, Vikram B, Yoo S, Chung C. Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. J Natl Cancer Inst, 2013. e-Pub 2013.
299. Lopez Guerra JL, Gomez DR, Lin SH, Levy LB, Zhuang Y, Komaki R, Jaen J, Vaporciyan AA, Swisher SG, Cox JD, Liao Z, Rice DC. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol 24(1):67-74, 2013. e-Pub 2013. PMID: 23002278.
300. Armini A, Feiran L, Corea AM, Baldessare R, Rimner A, Huang J, Roth JA, Swisher SG, Vaporciyan AA, Lin SH. Predictors for locoregional recurrence for clinical stage III-N2 non-small cell lung cancer with nodal downstaging after induction chemotherapy and surgery. Ann Surg Oncol 20:1934-40, 2013. e-Pub 2013.
301. Lin SH, Myles B, Wang L, Thall PF, Hofstetter WL, Swisher SG, Ajani JA, Cox JD, Komaki R, Liao Z. Propensity score based comparison of long term outcomes with 3D conformal radiotherapy (3DCRT) versus Intensity Modulated Radiation Therapy (IMRT) in treatment of esophageal cancer. Int J Radiat Oncol Biol Phy 84(5):1078-85, 2012. e-Pub 2012. PMID: 22867894.
302. Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Ajani JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer 48(18):3396-33404, 2012. e-Pub 2012. PMID: 22853875.
303. Saintigny P, Massarelli E, Lin SH, Ahn YH, Chen Y, Goswani S, Erez B. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Research, 2012. e-Pub 2012.
304. Ajani JA, Correa AM, Hofstetter WL, Rice DC, Blum MA, Suzuki A, Taketa T, Welsh J, Lin SH, Lee JH, Bhutani MS, Ross WA, Maru DM, Macapinlac HA, Erasmus J, Komaki R, Mehran RJ, Vaporciyan AA, Swisher SG. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol 23(10):2638-2642, 2012. e-Pub 2012. PMID: 22831985.
305. Xu T, Wei Q, Lopez Guerra JL, Wang LE, Liu Z, Gomez D, O'Reilly M, Lin SH, Zhuang Y, Levy LB, Mohan R, Zhou H, Liao Z. HSPB1 Gene Polymorphisms Predict Risk of Mortality for US Patients After Radio(chemo)therapy for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 84(2):e229-e235, 2012. e-Pub 2012. PMID: 22608953.
306. Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Suzuki A, Lee JH, Bhutani MS, Welsh J, Lin SH, Maru DM, Swisher SG, Ajani JA. Patients with high body mass index tend to have lower stage of esophageal carcinoma at diagnosis. Dis Esophagus 25(7):614-622, 2012. e-Pub 2012. PMID: 22150920.
307. Guerra JLL, Gomez D, Zhuang Y, Hong D, Heymach JV, Swisher SG, Lin SH, Komaki R, Cox JD, Liao Z. Prognostic impact of radiation therapy to the primary site in non-small cell lung cancer patients with oligometastasis at diagnosis. Int J Radiat Oncol Biol Phy 84(1):e61-e67, 2012. e-Pub 2012. PMID: 22503522.
308. Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA, Lin SH. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg 94(3):914-920, 2012. e-Pub 2012. PMID: 22819472.
309. Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, Ajani JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 83(3):e345-e351, 2012. e-Pub 2012. PMID: 22417808.
310. Yu ZH, Lin SH, Balter P, Zhang L, Dong L. A comparison of tumor motion characteristics between early stage and locally advanced stage lung cancers. Radiother Oncol 104(1):33-38, 2012. e-Pub 2012. PMID: 22677039.
311. Wang J, Lin SH, Dong L, Balter P, Mohan R, Komaki R, Cox JD, Starkschall G. Quantifying the Interfractional Displacement of the Gastroesophageal Junction during Radiation Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys 83(2):e273-e280, 2012. e-Pub 2012. PMID: 22440040.
312. Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, Ajani JA. Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation. Oncology 83(5):300-304, 2012. e-Pub 2012. PMID: 22964903.
313. Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, Ajani JA. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology 82(2):108-113, 2012. e-Pub 2012. PMID: 22328056.
314. Joy S, Starkschall G, Kry S, Salehpour M, White RA, Lin SH, Balter P. Dosimetric effects of jaw tracking in step-and-shoot intensity-modulated radiation therapy. J Appl Clin Med Phys 13(2):3707, 2012. e-Pub 2012. PMID: 22402386.
315. Amini A, Lin SH, Wei C, Allen P, Cox JD, Komaki R. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol 7:33, 2012. e-Pub 2012. PMID: 22420631.
316. Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, Ajani JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer 117(21):4822-4833, 2011. e-Pub 2011. PMID: 21456015.
317. Hristov B, Reddy S, LinSH, Cameron JL, Pawlik TM, Hruban RH, Swartz MJ, Edil BH, Kemp C, Wolfgang CL, Herman JM. Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 76(1):176-180, 2010. e-Pub 2010. PMID: 19394156.
318. Tan AC, Jimeno A, Lin SH, Wheelhouse J, Chan F, Solomon A, Rajeshkumar NV, Rubio-Viqueira B, Hidalgo M. Characterizing DNA methylation patterns in pancreatic cancer genome. Mol Oncol 3(5-6):425-438, 2009. e-Pub 2009. PMID: 19497796.
319. Yi JM, Tsai HC, Glöckner SC, Lin SH, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, Laterra J, Vescovi AL, Ahuja N, Herman JG, Schuebel KE, Baylin SB. Abnormal DNA methylation of CD133 in Colorectal and Glioblastoma Tumors. Cancer Res 68(19):8094-8103, 2008. e-Pub 2008. PMID: 18829568.
320. Lin SH, Sugar E, Teslow T, McNutt T, Saleh H, Song DY. Comparison of daily couch shifts using MVCT (TomoTherapy) and B-mode Ultrasound (BAT system) during prostate radiotherapy. Technol Cancer Res Treat 7(4):279-286, 2008. e-Pub 2008. PMID: 18642966.
321. Lin SH, Latronico D, Teslow T, Bajaj GK. A highly reproducible bolus immobilization technique for the treatment of scalp malignancies. Med Dosim 33(1):30-35, 2008. e-Pub 2008. PMID: 18262120.
322. Nagasaki H, Wang Z, Jackson VR, Lin SH, Nothacker HP, Civelli O. Differential expression of the thyrostimulin subunits, glycoprotein alpha2 and beta5 in the rat pituitary. J Mol Endocrinol 37(1):39-50, 2006. e-Pub 2006. PMID: 16901922.
323. Jackson VR, Lin SH, Wang Z, Nothacker HP, Civelli O. A study of the rat neuropeptide B/neuropeptide W system using in situ techniques. J Comp Neurol 497(3):367-383, 2006. e-Pub 2006. PMID: 16736466.
324. Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, Brucher FA, Zeng J, Ly NK, Henriksen SJ, de Lecea L, Civelli O. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43(4):487-497, 2004. e-Pub 2004. PMID: 15312648.
325. Lin SH, Leslie FM, Civelli O. Neurochemical properties of the prolactin releasing peptide (PrRP) receptor expressing neurons: evidence for a role of PrRP as a regulator of stress and nociception. Brain Res 952(1):15-30, 2002. e-Pub 2002. PMID: 12363400.
326. Lin SH, Arai AC, España RA, Berridge CW, Leslie FM, Huguenard JR, Vergnes M, Civelli O. Prolactin-releasing peptide (PrRP) promotes awakening and suppresses absence seizures. Neuroscience 114(1):229-238, 2002. e-Pub 2002. PMID: 12207968.
327. Lin SH, Arai AC, Wang Z, Nothacker HP, Civelli O. The carboxyl terminus of the prolactin-releasing peptide receptor interacts with PDZ domain proteins involved in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor clustering. Mol Pharmacol 60(5):916-923, 2001. e-Pub 2001. PMID: 11641419.
328. Nothacker HP, Wang Z, Zhu Y, Reinscheid RK, Lin SH, Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol 58(6):1601-1608, 2000. e-Pub 2000.
329. Saito Y, Nothacker HP, Wang Z, Lin SH, Leslie F, Civelli O. Molecular characterization of the melanin-concentrating hormone receptor. Nature 400(400):265-269, 1999. e-Pub 1999. PMID: 10421368.

Invited Articles

1. Xi M, Lin SH. Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer. Expert Rev Anticancer Ther, 2017. e-Pub 2017.
2. Verma V, Lin SH. Implications of the Bystander and Abscopal Effects of Radiation Therapy. Clin Cancer Res 22(19):4763-4765, 2016. e-Pub 2016. PMID: 27458248.
3. van Rossum PSN, Xu C, Fried DV, Goense L, Court LE, Lin SH. The emerging field of radiomics in esophageal cancer: current evidence and future potential. Transl Cancer Res 5(4):410-423, 2016. e-Pub 2016.
4. Lin SH. Invited Commentary: Prognostic significance of vascular and lymphatic emboli in resected pulmonary adenocarcinoma. Ann Thorac Surg 95(4):1210-1211, 2013. e-Pub 2013.
5. Lin SH. The utility of protonbBeam therapy with concurrent chemotherapy for the treatment of esophageal cancers. Cancers (Basel) 3(4):4090-4101, 2011. e-Pub 2011. PMID: 24213126.
6. Lin SH, Chang JY. Esophageal Cancer: Diagnosis and Management. Chinese Journal of Cancer 29(8):67-78, 2010. e-Pub 2010.

Review Articles

1. López Moreno, SF, Lenz, SA, Casso-Chapa, B, Paniagua Bojorges, A, Kim, JH, Palaskas, NL, Nead, KT, Samanthapudi, VS, Mejia, G, Hoang, ON, Lee, J, Lin, SH, Herrmann, J, Wang, G, Yusuf, SW, Iliescu, C, Beinart, N, Manisty, C, Ushio-Fukai, M, Fukai, T, Ameri, P, Nurieva, R, Hildebrandt, MA, Schadler, KL, Koutroumpakis, E, Kotla, S, Le, NT, Abe, J. SHP2. Antioxidants 14(12), 2025. e-Pub 2025. PMID: 41462587.
2. Abe, J, Chau, KM, Mojiri, A, Wang, G, Oikawa, M, Samanthapudi, VS, Osborn, AM, Ostos-Mendoza, KC, Mariscal-Reyes, KN, Mathur, T, Jain, A, Herrmann, J, Yusuf, SW, Krishnan, S, Deswal, A, Lin, SH, Kotla, S, Cooke, J, Le, NT. Impacts of Radiation on Metabolism and Vascular Cell Senescence. Antioxidants and Redox Signaling 43(1-3):92-114, 2025. e-Pub 2025. PMID: 40233257.
3. Ozair, MZ, Halmos, B, D'Aiello, A, Yun, J, Filippi, AR, Rimner, A, Lin, SH, Simone, C, Ohri, N. Chemotherapy-Free Treatment with Radiotherapy and Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer. Cancers 17(9), 2025. e-Pub 2025. PMID: 40361451.
4. Casso-Chapa, B, Vazquez González, NA, Le, NT, Palaskas, NL, Nead, KT, Eutsey, LP, Samanthapudi, VS, Osborn, AM, Lee, J, Mejia, G, Hoang, ON, Lin, SH, Deswal, A, Herrmann, J, Wang, G, Kirkland, J, Krishnan, S, Wehrens, XH, Chini, EN, Yusuf, SW, Iliescu, C, Jain, A, Burks, JK, Seeley, EH, Lorenzi, PL, Chau, KM, Ostos-Mendoza, KC, Grumbach, IM, Brookes, PS, Hanssen, NM, de Winther, M, Yvan-Charvet, L, Kotla, S, Schadler, KL, Abe, J. Reevaluating Anti-Inflammatory Therapy. Arteriosclerosis, thrombosis, and vascular biology 45(3):372-385, 2025. e-Pub 2025. PMID: 39817327.
5. Zumsteg, ZS, Sheth, S, Jabbour, SK, Patel, KR, Kimple, RJ, Williams, TM, Welliver, MX, Torres-Saavedra, P, Monjazeb, AM, Mayadev, J, Finkelstein, SE, Buatti, JM, Patel, SP, Lin, SH. Challenges and opportunities for early phase clinical trials of novel drug–radiotherapy combinations. The lancet oncology 25(10):e489-e500, 2024. e-Pub 2024. PMID: 39362260.
6. Banerjee, P, Rosales, JE, Chau, KM, Nguyen, MT, Kotla, S, Lin, SH, Deswal, A, Dantzer, R, Olmsted-Davis, EA, Nguyen, H, Wang, G, Cooke, J, Abe, J, Le, NT. Possible molecular mechanisms underlying the development of atherosclerosis in cancer survivors. Frontiers in Cardiovascular Medicine 10, 2023. e-Pub 2023. PMID: 37332576.
7. Nelson BE, Adashek JJ, Lin SH, Subbiah V. The abscopal effect in patients with cancer receiving immunotherapy. Med 4(4):233-244, 2023. e-Pub 2023. PMID: 36893753.
8. Joo L, Bradley CC, Lin SH, Scheet PA, Nead KT. Causes of Clonal Hematopoiesis: a Review. Curr Oncol Rep 25(3):211-220, 2023. e-Pub 2023. PMID: 36719597.
9. Nelson BE, Adashek JJ, Lin SH, Subbiah V. On target methods to induce abscopal phenomenon for Off-Target effects: From happenstance to happenings. Cancer Med 12(6):6451-6465, 2023. e-Pub 2023. PMID: 36411943.
10. Jain, A, Casanova, D, Padilla, AV, Paniagua Bojorges, A, Kotla, S, Ko, KA, Samanthapudi, VS, Chau, KM, Nguyen, MT, Wen, J, Hernandez Gonzalez, SL, Rodgers, SP, Olmsted-Davis, EA, Hamilton, DJ, Reyes-Gibby, CC, Yeung, SJ, Cooke, J, Herrmann, J, Chini, EN, Xu, X, Yusuf, SW, Yoshimoto, M, Lorenzi, PL, Hobbs, BP, Krishnan, S, Koutroumpakis, E, Palaskas, NL, Wang, G, Deswal, A, Lin, SH, Abe, J, Le, NT. Premature senescence and cardiovascular disease following cancer treatments. Frontiers in Cardiovascular Medicine 10, 2023. e-Pub 2023. PMID: 37781317.
11. Verma V, Yegya-Raman N, Sprave T, Han G, Kantarjian HM, Welsh JW, Chang JY, Lin SH. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases. Int J Radiat Oncol Biol Phys 114(5):977-988, 2022. e-Pub 2022. PMID: 35675852.
12. Verma, V, Lin, SH. Proton beam radiotherapy for esophageal cancer. Precision Radiation Oncology 6(3):257-261, 2022. e-Pub 2022.
13. Banerjee, P, Olmsted-Davis, EA, Deswal, A, Nguyen, MT, Koutroumpakis, E, Palaskas, NL, Lin, SH, Kotla, S, Reyes-Gibby, CC, Yeung, SJ, Yusuf, SW, Yoshimoto, M, Kobayashi, M, Yu, B, Schadler, KL, Herrmann, J, Cooke, J, Jain, A, Chini, EN, Le, NT, Abe, J. Cancer treatment-induced NAD+ depletion in premature senescence and late cardiovascular complications. Journal of Cardiovascular Aging 2(3), 2022. e-Pub 2022. PMID: 35801078.
14. Koutroumpakis, E, Deswal, A, Yusuf, SW, Abe, J, Nead, KT, Potter, A, Liao, Z, Lin, SH, Palaskas, NL. Radiation-Induced Cardiovascular Disease. Current oncology reports 24(5):543-553, 2022. e-Pub 2022. PMID: 35192118.
15. Tomassen, ML, Pomp, J, van der Stap, J, van Lindert, AS, Peters, M, Belderbos, JS, De Ruysscher, DK, Lin, SH, Verhoeff, JJ, van Rossum, P. The overall survival impact of prophylactic cranial irradiation in limited-stage small-cell lung cancer. Clinical and Translational Radiation Oncology 33:145-152, 2022. e-Pub 2022. PMID: 35243025.
16. Damen PJJ, Kroese TE, van Hillegersberg R, Schuit E, Peters M, Verhoeff JJC, Lin SH, van Rossum PSN. The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys, 2021. e-Pub 2021. PMID: 34329738.
17. Koutroumpakis E, Palaskas NL, Lin SH, Abe JI, Liao Z, Banchs J, Deswal A, Yusuf SW. Modern Radiotherapy and Risk of Cardiotoxicity. Chemotherapy:1-12, 2020. e-Pub 2020. PMID: 33049738.
18. Moreno AC, Lin SH. The optimal treatment approaches for stage I small cell lung cancer. Transl Lung Cancer Res 8(1):88-96, 2019. e-Pub 2019. PMID: 30788238.
19. Badiyan SN, Hallemeier CL, Lin SH, Hall MD, Chuong MD. Proton beam therapy for gastrointestinal cancers: past, present, and future. J Gastrointest Oncol 9(5):962-971, 2018. e-Pub 2018. PMID: 30505599.
20. Liao Z, Gandhi SJ, Lin SH, Bradley J. Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors?. Semin Radiat Oncol 28(2):114-124, 2018. e-Pub 2018. PMID: 29735187.
21. Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol 123:42-51, 2018. e-Pub 2018. PMID: 29482778.
22. Deng W, Lin SH. Advances in radiotherapy for esophageal cancer. Ann Transl Med 6(4):79, 2018. e-Pub 2018. PMID: 29666802.
23. Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, Lin SH. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Front Pharmacol 9:185, 2018. e-Pub 2018. PMID: 29556198.
24. Jamorabo DS, Lin SH, Jabbour SK. Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies: New Directions. Semin Radiat Oncol 26(4):307-19, 2016. e-Pub 2016. PMID: 27619252.
25. Chuong MD, Hallemeier CL, Jabbour SK, Yu J, Badiyan S, Merrell KW, Mishra MV, Li H, Verma V, Lin SH. Improving Outcomes for Esophageal Cancer using Proton Beam Therapy. Int J Radiat Oncol Biol Phys 95(1):488-497, 2016. e-Pub 2016. PMID: 27084662.
26. Chung H, Court L, Lin SH, Kulkarni D, Balter P. Evaluation of dose variation to normal and critical structures for lung hypofractionated stereotactic body radiation therapy. Pract Radiat Oncol 2(3):e15-e21, 2012. e-Pub 2012. PMID: 24674129.
27. Liao Z, Lin SH, Cox JD. Status of Particle therapy for lung cancer. Acta Oncol 50(6):745-756, 2011. e-Pub 2011. PMID: 21767170.
28. Lin SH, Kleinberg LR. Carmustine Wafers: Localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8(3):343-359, 2008. e-Pub 2008. PMID: 18366283.
29. Lin SH. Prolactin Releasing Peptide. Results Probl Cell Differ 46:57-88, 2008. e-Pub 2008. PMID: 18204826.
30. Lin SH, Civelli O. Orphan G protein-coupled receptors: targets for new therapeutic interventions. Ann Med 36(3):204-214, 2004. e-Pub 2004. PMID: 15181976.
31. Civelli O, Nothacker HP, Saito Y, Wang Z, Lin SH, Reinscheid RK. Novel neurotransmitters as natural ligands of orphan G protein-coupled receptors. Trends Neurosci 24(4):230-237, 2001. e-Pub 2001. PMID: 11250008.

Other Articles

1. Ohannesian, N, Mallick, MS, He, J, Qiao, Y, Li, N, Shaitelman, SF, Tang, C, Shinn, EH, Hofstetter, WL, Goltsov, A, Hassan, MM, Hunt, KK, Lin, SH, Shih, WC Correction to. Communications Medicine 4(1), 2024. PMID: 38942807.

Editorials

1. Damen, PJ, Lin, SH, van Rossum, P. Editorial. Frontiers in Oncology 14, 2024. PMID: 39015501.
2. Xu C, Lin SH. Deciding on the neoadjuvant approach for esophageal adenocarcinomas. J Thorac Dis 9(7):1818–1821, 2017.

Abstracts

1. Zhou N, Hofstetter WL, Working Group ESCC, Mitchell KG, Bayley EM, Ajani JA, Antonoff MB, Betancourt SL, Blum-Murphy M, Feldman HA, Lin SH, Maru DM, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Weston BR. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. The Annals of Thoracic Surgery, 2021. e-Pub 2021.

Book Chapters

1. Lin, SH, Raben, D. Optimizing Drug Therapies in the Maintenance Setting After Radiochemotherapy in Non-small Cell Lung Cancer, 571-580, 2023.
2. Ning, M, Verma, V, Lin, SH. Thoracic Malignancies, 261-285, 2022.
3. Lin SH, Komaki R. Molecular Targeted Treatment for Personalized Radiotherapy in Lung Cancer. In: Lung Cancer. 4th Edition. John Wiley & Sons, Inc, 2014.
4. Lin SH. Adjuvant Therapy for NSCLC Following Surgical Resection. In: Personalized Management of Lung Cancer. Future Science Group (FSG), 2013.
5. Lin SH, Lee VJ. Ear Cancer. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 538-539, 2010.
6. Lin SH, Roland E. Melanoma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 521-528, 2010.
7. Lin SH, Rengan R. Hemangiopericytoma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 510-511, 2010.
8. Lin SH, Alonso-Basanta M. Chordoma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 498-501, 2010.
9. Lin SH, Plastaras JP. MALT Lymphoma (Gastric and Ocular Adnexa and Other Sites). In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 472-477, 2010.
10. Lin SH, Glatstein E. Hodgkin Disease. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 457-464, 2010.
11. Lin SH, Liao Z. Esophageal Cancer. In: Radiation Oncology A Question Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 285-296, 2010.
12. Lin SH, Zellars RC. Early-Stage (I-II) Breast Cancer. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 260-272, 2010.
13. Lin SH, Bucci KM. Pleural Mesothelioma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 238-246, 2010.
14. Lin SH, Jeter MD. Thymoma and Thymic Carcinoma. In: Radiation Oncology a Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 232-238, 2010.
15. Lin SH, Welsh J. Advanced-Stage (III-IV) Non-Small Cell Lung Cancer. In: Radation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 209-222, 2010.
16. Lin SH, Lee VJ. Neck Management and Postoperative Radiation Therapy for Head and Neck Cancers. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 195-198, 2010.
17. Lin SH, Bajaj GK. Laryngeal and Hypopharyngeal Cancers. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 172-182, 2010.
18. Lin SH, Sanguineti G. Oropharyngeal Cancer. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 157-165, 2010.
19. Lin SH, Bajaj GK. Oral Cavity Cancer. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 149-157, 2010.
20. Lin SH, Lee VJ. Ocular Melanoma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 123-129, 2010.
21. Lin SH, Chan TA. Primary Central Nervous System Lymphoma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/lippincott Williams & Wilkins, 91-98, 2010.
22. Lin SH, Woo SY. High -Grade Glioma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 82-88, 2010.
23. Lin SH, Mahajan A. General Central Nervous System. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 73-76, 2010.
24. Lin SH, Ori S. Hemangioblastoma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 67-69, 2010.
25. Hristov B, Lin SH, Christodouleas JP. Ependymoma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 54-58, 2010.
26. Hristov B, Lin SH, Christodouleas JP. Rhabdomyosarcoma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 1-12, 2010.
27. Lin SH, Ori S. Brainstem Glioma. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 70-72, 2010.
28. Lin SH, Jabbour S. Gastric Cancer. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 296-304, 2010.
29. Lin SH, Chang JY. Lung Cancer. In: Decision Making in Radiation Oncology. 2nd Edition. Springer-Verlag, 261-307, 2010.
30. Lin SH, Liao Z. Esophageal Cancer. In: Decision Making in Radiation Oncology. 2nd Edition. Springer-Verlag, 329-358, 2010.
31. Lin SH, Wharam, Jr MD. Wilms Tumor. In: Radiation Oncology A Question-Based Review. Wolters Kluwer/Lippincott Williams & Wilkins, 20-30, 2010.

Books (edited and written)

1. Hristov B, Lin SH, Christodouleas JP. Radiation Oncology: A Question-based Review. Ed(s) 2nd edition. Wolters Kluwer, Lippincott, Williams & Wilkins, 2014.
2. Hristov B, Lin SH, Christodouleas JP. Radiation Oncology: A Question-based Review. Ed(s) 1st Edition. Wolters Kluwer, Lippincott, Williams & Wilkins, 2011.

Patents

1. Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP). Patent Number: 6,383,764.
2. Screening and therapeutic methods for promoting wakefulness and sleep. Patent Number: 6,884,596.